var title_f5_5_5200="Appendiceal anatomy";
var content_f5_5_5200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Variations in the position of the appendix",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 558px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5200=[""].join("\n");
var outline_f5_5_5200=null;
var title_f5_5_5201="EMR band snare technique";
var content_f5_5_5201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Picture demonstrating the band and snare technique for endoscopic mucosal resection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The top panels show the lesion ensnared with a variceal band ligator. A polypectomy snare is used to remove the tissue (lower left panel), leaving the residual mucosal defects (lower right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher Gostout, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5201=[""].join("\n");
var outline_f5_5_5201=null;
var title_f5_5_5202="Decompression of the pancreatic duct";
var content_f5_5_5202=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Decompression of the pancreatic duct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Endoscopic retrograde cholangiopancreatography (ERCP) shows a dilated pancreatic duct with a stone at the junction between the head and body of the pancreas (white arrow).",
"    <br>",
"     (B) After external shock wave lithotripsy, the pancreatic stone is fractured (black arrow).",
"     <br>",
"      (C)&nbsp;ERCP after the&nbsp;stone fragments are removed with a balloon or basket.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Moises Guelrud, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5202=[""].join("\n");
var outline_f5_5_5202=null;
var title_f5_5_5203="Hirsutism in PCOS";
var content_f5_5_5203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F73544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F73544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hirsutism in PCOS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5203=[""].join("\n");
var outline_f5_5_5203=null;
var title_f5_5_5204="Guaifenesin: Pediatric drug information";
var content_f5_5_5204=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Guaifenesin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16101?source=see_link\">",
"    see \"Guaifenesin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/55/26484?source=see_link\">",
"    see \"Guaifenesin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Allfen [OTC] [DSC];",
"     </li>",
"     <li>",
"      Bidex&reg;-400 [OTC];",
"     </li>",
"     <li>",
"      Diabetic Siltussin DAS-Na [OTC];",
"     </li>",
"     <li>",
"      Diabetic Tussin&reg; EX [OTC];",
"     </li>",
"     <li>",
"      Fenesin IR [OTC];",
"     </li>",
"     <li>",
"      Geri-Tussin [OTC];",
"     </li>",
"     <li>",
"      Humibid&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Iophen NR [OTC];",
"     </li>",
"     <li>",
"      Liquituss GG [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Kid's Mini-Melts&trade; [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Kid's [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Mucinex&reg; [OTC];",
"     </li>",
"     <li>",
"      Mucus Relief [OTC];",
"     </li>",
"     <li>",
"      Organ-I NR [OTC];",
"     </li>",
"     <li>",
"      Q-Tussin [OTC];",
"     </li>",
"     <li>",
"      Refenesen&trade; 400 [OTC];",
"     </li>",
"     <li>",
"      Refenesen&trade; [OTC];",
"     </li>",
"     <li>",
"      Robafen [OTC];",
"     </li>",
"     <li>",
"      Scot-Tussin&reg; Expectorant [OTC];",
"     </li>",
"     <li>",
"      Siltussin SA [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Casero&trade; Chest Congestion Relief [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; DayQuil&reg; Mucus Control [OTC];",
"     </li>",
"     <li>",
"      Xpect&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Balminil Expectorant;",
"     </li>",
"     <li>",
"      Benylin&reg; E Extra Strength;",
"     </li>",
"     <li>",
"      Koffex Expectorant;",
"     </li>",
"     <li>",
"      Robitussin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Expectorant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16101?source=see_link\">",
"      see \"Guaifenesin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;2 years: 12 mg/kg/day in 6 divided doses or as an alternative:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-5 years: 50-100 mg every 4 hours, not to exceed 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-11 years: 100-200 mg every 4 hours or as extended release product 600 mg every 12 hours; not to exceed 1.2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years and Adults: 200-400 mg every 4 hours or as extended release product 600-1200 mg every 12 hours; not to exceed 2.4 g/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fenesin IR: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Refenesen&trade; 400: 400 mg [dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; Kid's Mini-Melts&trade;: 50 mg/packet (12s) [contains magnesium 6 mg/packet, phenylalanine 0.6 mg/packet, sodium 2 mg/packet; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; Kid's Mini-Melts&trade;: 100 mg/packet (12s) [contains magnesium 6 mg/packet, phenylalanine 1 mg/packet, sodium 3 mg/packet; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diabetic Tussin&reg; EX: 100 mg/5 mL (118 mL) [dye free, ethanol free, sugar free; contains phenylalanine 8.4 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Iophen NR: 100 mg/5 mL (480 mL) [contains propylene glycol, sodium 2 mg/5 mL, sodium benzoate; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liquituss GG: 200 mg/5 mL (118 mL, 473 mL) [ethanol free, sugar free; contains potassium 30 mg/5 mL, propylene glycol, sodium 2 mg/5 mL; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; Kid's: 100 mg/5 mL (118 mL) [contains propylene glycol, sodium 3 mg/5 mL; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-Tussin: 100 mg/5 mL (118 mL, 237 mL, 473 mL) [ethanol free; contains sodium 2 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Scot-Tussin&reg; Expectorant: 100 mg/5 mL (120 mL) [dye free, ethanol free, sugar free; contains benzoic acid; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; Casero&trade; Chest Congestion Relief: 100 mg/6.25 mL (120 mL, 240 mL) [contains phenylalanine 5.5 mg/12.5 mL, sodium 32 mg/12.5 mL, sodium benzoate; honey-menthol flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; DayQuil&reg; Mucus Control: 200 mg/15 mL (295 mL) [contains propylene glycol, sodium 25 mg/15 mL, sodium benzoate; citrus blend flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: 100 mg/5 mL (5 mL, 10 mL, 15 mL, 118 mL, 240 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diabetic Siltussin DAS-Na: 100 mg/5 mL (118 mL) [ethanol free, sugar free; contains benzoic acid, phenylalanine 3 mg/5 mL, propylene glycol; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Geri-Tussin: 100 mg/5 mL (480 mL) [ethanol free, sugar free; contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robafen: 100 mg/5 mL (120 mL, 240 mL, 480 mL) [ethanol free; contains sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Siltussin SA: 100 mg/5 mL (120 mL, 240 mL, 480 mL) [ethanol free, sugar free; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allfen: 400 mg [DSC] [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bidex&reg;-400: 400 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucus Relief: 400 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucus Relief: 400 mg [dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Organ-I NR: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Refenesen&trade;: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xpect&trade;: 400 mg [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Humibid&reg; Maximum Strength: 1200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg;: 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mucinex&reg; Maximum Strength: 1200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet and granules",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with a large quantity of fluid to ensure proper action; do not crush or chew extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Expectorant used for the symptomatic treatment of coughs",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F177639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       GuaiFENesin may be confused with guanFACINE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mucinex&reg; may be confused with Mucomyst&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F177637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Uric acid levels decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, stomach pain, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Kidney stone formation (with consumption of large quantities)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to guaifenesin or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products contain phenylalanine which must be used with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy for the use of cough and cold products in children &lt;2 years of age is limited. Serious adverse effects including death have been reported. The FDA notes that there are no approved OTC uses for these products in children &lt;2 years of age. Healthcare providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some products contain sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites; avoid use of products containing sodium benzoate in neonates. Some forms contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use forms containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5630929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on the limited available data, an increased risk of adverse birth outcomes has not been observed following maternal use of guaifenesin in pregnancy. Alcohol may be present in some liquid formulations of guaifenesin. If consumed in sufficient quantities during pregnancy, fetal alcohol syndrome may result. Guaifenesin has been investigated as an agent to improve cervical mucus and improve fertility.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thought to act as an expectorant by irritating the gastric mucosa and stimulating respiratory tract secretions, thereby increasing respiratory fluid volumes and decreasing phlegm viscosity",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Well absorbed",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/5/5204/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13343 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5204=[""].join("\n");
var outline_f5_5_5204=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177599\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177600\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059071\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059067\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177583\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177570\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059075\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059074\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177639\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177637\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059078\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059066\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059065\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299423\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220718\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5630929\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059064\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059077\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13343\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13343|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16101?source=related_link\">",
"      Guaifenesin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/55/26484?source=related_link\">",
"      Guaifenesin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_5_5205="Magnesium oxide: Pediatric drug information";
var content_f5_5_5205=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Magnesium oxide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28165?source=see_link\">",
"    see \"Magnesium oxide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/33/12820?source=see_link\">",
"    see \"Magnesium oxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Mag-Ox&reg; 400 [OTC];",
"     </li>",
"     <li>",
"      MAGnesium-Oxide&trade; [OTC];",
"     </li>",
"     <li>",
"      Phillips'&reg; Laxative Dietary Supplement Cramp-Free [OTC];",
"     </li>",
"     <li>",
"      Uro-Mag&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1023112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Laxative, Osmotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Magnesium Salt",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F13292080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommended daily allowance of magnesium: Oral: 40 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1023134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28165?source=see_link\">",
"      see \"Magnesium oxide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recommended daily allowance of magnesium: See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Magnesium &minus; Recommended Daily Allowance (RDA) and Estimated Average Requirement (EAR) (in terms of elemental magnesium)",
"     </caption>",
"     <col align=\"left\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Age",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         RDA",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/day)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         EAR",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/day)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         1 to &lt;6 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         6 to &lt;12 mo",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         1-3 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         80",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         65",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         4-8 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         130",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         110",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Male",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         9-13 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         240",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         14-18 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         410",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         340",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Female",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         9-13 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         240",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;margin-left:2em;\">",
"         14-18 y",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         360",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         300",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Antacid: Adults: 140 mg 3-4 times/day or 400-840 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cathartic: Adults: 2-4 g at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypomagnesemia:",
"     <b>",
"      Note:",
"     </b>",
"     Achieving optimal magnesium levels using oral therapy may be difficult due to the propensity for magnesium to cause diarrhea: I.V. replacement may be more appropriate particularly in situations of severe deficit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 10-20 mg/kg elemental magnesium per dose up to 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Patients in severe renal failure should not receive magnesium due to toxicity from accumulation. Patients with a Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute receiving magnesium should have serum magnesium levels monitored.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral: Elemental magnesium 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phillips'&reg; Laxative Dietary Supplement Cramp-Free: Elemental magnesium 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uro-Mag&reg;: 140 mg [equivalent to elemental magnesium 84.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 400 mg [equivalent to elemental magnesium 240 mg], 400 mg [equivalent to elemental magnesium 241.3 mg], 420 mg [equivalent to elemental magnesium 253 mg], 500 mg [equivalent to elemental magnesium 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mag-Ox&reg; 400: 400 mg [scored; equivalent to elemental magnesium 240 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MAGnesium-Oxide&trade;: 400 mg [equivalent to elemental magnesium 240 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3416829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Tablet: Take with full glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1023113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium supplement; short-term treatment of constipation; treatment of hyperacidity symptoms",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F191011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Gastrointestinal: Diarrhea (excessive oral doses)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1023115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to magnesium salt(s) or any component; serious renal impairment, myocardial damage, heart block; patients with colostomy or ileostomy, intestinal obstruction, impaction, or perforation, appendicitis, abdominal pain",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3416826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal function (accumulation of magnesium may lead to magnesium intoxication)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1023116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple salt forms of magnesium exist; close attention must be paid to the salt form when ordering and administering magnesium;",
"     <b>",
"      incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or under-dosing",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F190977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3013029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Magnesium crosses the placenta; serum concentrations in the fetus are similar to those in the mother (Osada, 2002; Idama, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1023130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neonates and Infants: 1.5-2.3 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 1.5-2.0 mEq/L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 1.4-2.0 mEq/L",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3416827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium is important as a cofactor in many enzymatic reactions in the body. There are at least 300 enzymes which are dependent upon magnesium for normal functioning. Actions on lipoprotein lipase have been found to be important in reducing serum cholesterol. Magnesium is necessary for the maintaining of serum potassium and calcium levels due to its effect on the renal tubule. In the heart, magnesium acts as a calcium channel blocker. It also activates sodium potassium ATPase in the cell membrane to promote resting polarization and produce arrhythmias. Promotes bowel evacuation by causing osmotic retention of fluid which distends the colon and produces increased peristaltic activity when taken orally. To reduce stomach acidity, it reacts with hydrochloric acid in the stomach to form magnesium chloride",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1023131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Up to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renal with unabsorbed drug excreted in feces",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F3426372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Magnesium oxide 500 mg = 302 mg",
"     <b>",
"      elemental",
"     </b>",
"     magnesium = 25 mEq magnesium",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Magnesium Content of Magnesium Salts",
"     </caption>",
"     <col align=\"left\" width=\"190\">",
"     </col>",
"     <col align=\"center\" width=\"150\">",
"     </col>",
"     <col align=\"center\" width=\"160\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Magnesium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/500 mg salt)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mEq/500 mg salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium chloride",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.9",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         27",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2.4",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium L-aspartate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         49.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium oxide",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         302",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Magnesium sulfate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         49.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.1",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adverse effects associated with elevated serum magnesium concentrations may include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;3 mg/dL: Blocked peripheral neuromuscular transmission leading to anticonvulsant effects, depressed CNS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;5 mg/dL: Depressed deep tendon reflexes, flushing, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &gt;12 mg/dL: Complete heart block, respiratory paralysis",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12981 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-AF7A4312D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5205=[""].join("\n");
var outline_f5_5_5205=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190993\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023112\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13292080\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023134\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190981\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190969\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416829\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023113\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191011\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023115\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416826\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023116\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299638\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190977\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3013029\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023130\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3416827\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1023131\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3426372\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12981\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12981|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28165?source=related_link\">",
"      Magnesium oxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/33/12820?source=related_link\">",
"      Magnesium oxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_5_5206="MRI acute cholecystitis";
var content_f5_5_5206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatography (MRCP) in a patient with acute cholecystitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI and MRCP images from a patient with acute cholecystitis. Contrast enhanced (A) and fat saturated T2 weighted imaging (B) reveal a hyperemic gallbladder wall (white arrowheads). Multiple small stones are noted lying dependently in the base of the gallbladder (white arrow). The MRCP&nbsp;in the coronal&nbsp; projections (C and D)&nbsp;reveals accumulation of pericholecystic fluid (short yellow arrows). These findings are consistent with the diagnosis of acute cholecystitis",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5206=[""].join("\n");
var outline_f5_5_5206=null;
var title_f5_5_5207="Traction tracheomegaly";
var content_f5_5_5207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80220%7EPULM%2F55049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80220%7EPULM%2F55049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Traction tracheomegaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph from a patient with post-primary tuberculosis demonstrates tracheomegaly, upper lobe fibrosis with volume loss, bronchiectasis, emphysema, and bibasilar pleural scarring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Traction tracheomegaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest computed tomographic scan showing massive dilation and displacement of the trachea following right pneumonectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5207=[""].join("\n");
var outline_f5_5_5207=null;
var title_f5_5_5208="Japanese encephalitis: Epidemiology, diagnosis, treatment and prevention";
var content_f5_5_5208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Japanese encephalitis: Epidemiology, diagnosis, treatment and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/5/5208/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/5/5208/contributors\">",
"     Susan L Hills, MBBS, MTH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/5/5208/contributors\">",
"     Marc Fischer, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/5/5208/contributors\">",
"     Tom Solomon, FRCP, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/5/5208/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/5/5208/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/5/5208/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/5/5208/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/5/5208/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Japanese encephalitis virus (JEV), a mosquito-borne flavivirus, is the most important cause of viral encephalitis in Asia based on its frequency and severity. With the near eradication of poliomyelitis, JEV is now the leading cause of childhood viral neurological infection and disability in Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/1\">",
"     1",
"    </a>",
"    ]. JEV is closely related to West Nile, St. Louis encephalitis, and Murray Valley encephalitis viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About 68,000 cases of Japanese encephalitis (JE) are estimated to occur each year. JEV is endemic throughout most of Asia and parts of the western Pacific, but local transmission has not been observed in Africa, Europe, or the Americas. For travelers to Asia the risk of JE is very low but varies based on season, destination, duration, and activities [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/3\">",
"     3",
"    </a>",
"    ]. The estimated incidence of JE among travelers to Asia from non-endemic countries is &lt;1 case per 1 million travelers. Risk is likely to be higher for expatriates or travelers with longer duration of travel or whose plans include extensive outdoor activities in rural areas [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/3\">",
"     3",
"    </a>",
"    ]. Since 1973, only 56 cases of JE among travelers from non-endemic countries have been reported in the literature; since a JE vaccine was licensed in the United States in 1992, only seven cases of JE have been reported among United States travelers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most human JEV infections are asymptomatic or cause a non-specific febrile illness. Less than 1 percent of JEV infections results in symptomatic neuroinvasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/6\">",
"     6",
"    </a>",
"    ]. However, when neurological disease does occur, it is usually very severe with a high case fatality rate; among survivors, neurological sequelae are common. All travelers to JEV-endemic countries should be given advice on measures to prevent JE, and JE should be considered among the differential diagnoses for patients with suspected neurological infection who have returned from recent travel in a JEV-endemic country in Asia or the Western Pacific region.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Japanese encephalitis (JE) is endemic throughout most of Asia and parts of the Western Pacific region (",
"    <a class=\"graphic graphic_figure graphicRef52734 \" href=\"UTD.htm?22/33/23063\">",
"     figure 1",
"    </a>",
"    ). Within the JE-endemic region, there are two typical patterns of transmission:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In areas with temperate climates (including China, Japan, South Korea, Nepal, northern Vietnam, and northern India), most cases occur over a period of several months when the weather is warmest, usually after the monsoons begin or associated with heavy rainfall [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/2,7,8\">",
"       2,7,8",
"      </a>",
"      ]. The peak months of transmission and the length of the season vary from place to place. There are sometimes large, explosive outbreaks.",
"     </li>",
"     <li>",
"      In areas with tropical climates (including Cambodia, Indonesia, southern Vietnam, and southern Thailand), there is year-round transmission. An increase in cases may be observed during the rainy season [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In endemic areas, JE typically affects children &lt;15 years of age; by early adulthood the majority of the population has protective immunity following natural exposure to Japanese encephalitis virus (JEV) as a result of ongoing environmental transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/11\">",
"     11",
"    </a>",
"    ]. However, when the virus enters new geographic areas where there is no immunity, JE affects both adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/9\">",
"     9",
"    </a>",
"    ]. In regions where childhood immunization programs have been introduced, the age distribution of disease shifts to older ages [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. Among immunologically na&iuml;ve travelers visiting JEV-endemic regions, the disease can affect individuals at any age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Japanese encephalitis virus (JEV) is transmitted in an enzootic cycle involving mosquitoes and vertebrate amplifying hosts, primarily pigs and wading birds. Humans are incidental and dead end hosts in the JEV transmission cycle, as they do not develop sufficiently high viremia to infect feeding mosquitoes. Therefore, mosquitoes do not transmit the virus directly from one person to another person.",
"   </p>",
"   <p>",
"    Mosquitoes of the Culex vishnui subgroup, particularly Cx. tritaeniorhynchus, are the major vectors of JEV, although JEV has been isolated from over 30 mosquito species [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/14\">",
"     14",
"    </a>",
"    ]. Cx. tritaeniorhynchus commonly breeds in rice fields, marshes, and other shallow pools of water. It is an evening and nighttime biting mosquito and mainly feeds outdoors, preferentially on large animals and birds and only infrequently on humans.",
"   </p>",
"   <p>",
"    Pigs and wading birds, such as herons and egrets, are the most important hosts for maintenance and amplification of JEV. Pigs are a key host as they develop high levels of viremia and in Asia large numbers of pigs are frequently kept near human dwellings. In addition, the population of susceptible pigs is replenished regularly because of commercial slaughtering [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/9\">",
"     9",
"    </a>",
"    ]. JEV infection in pigs is usually asymptomatic, but gestational infection can result in abortions and stillbirths [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/6\">",
"     6",
"    </a>",
"    ]. The strong epidemiological link with pigs in the JEV transmission cycle has sometimes led to the misconception that areas without pigs are likely to be free of disease. However, transmission in such areas has also been documented, likely secondary to infection in wading birds [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk for JEV infection is highest in rural, agricultural areas of Asia, as all the elements of the enzootic transmission cycle are in close proximity to humans. However, JE cases are occasionally reported from urban or peri-urban areas [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly recognized clinical presentation of Japanese encephalitis (JE) is acute encephalitis. Milder forms of disease such as aseptic meningitis or non-specific febrile illness with headache also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/1\">",
"     1",
"    </a>",
"    ]. After an incubation period of 5 to 15 days, initial symptoms are usually non-specific and may include fever, diarrhea, and rigors followed by headache, vomiting, and generalized weakness. Over the next few days, mental status changes, focal neurologic deficits (including paresis, hemiplegia, tetraplegia, or cranial nerve palsies),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    movement disorders develop [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/6,16\">",
"     6,16",
"    </a>",
"    ]. Many patients lapse into coma and some require ventilatory assistance.",
"   </p>",
"   <p>",
"    In some patients, the initial presentation may consist of abnormal behavior or acute psychosis, leading to potential misdiagnosis. For example, during the Korean War in the 1950s, some American soldiers presenting with JE were initially thought to have \"war neurosis\" [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seizures (usually generalized tonic-clonic) are very common, especially among children. In some children subtle motor seizures occur and may present with twitching of a digit, eye deviation, or irregular breathing. These may be missed without electroencephalogram (EEG) monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/18\">",
"     18",
"    </a>",
"    ]. A very distinctive clinical presentation of JE is a Parkinsonian syndrome resulting from extrapyramidal involvement; findings include a dull, flat, mask-like faces with unblinking eyes, tremor, and cogwheel rigidity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some patients Japanese encephalitis virus (JEV) infection may present with a poliomyelitis-like acute flaccid paralysis due to anterior horn cell damage, without any alteration in consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. After a brief febrile illness, paralysis occurs in one or more limbs, usually asymmetric and more common in the lower than upper limbs. In these patients, encephalitis develops subsequently in about 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical signs associated with a poor prognosis include multiple, prolonged seizures and raised intracranial pressure. Changes in the respiratory pattern, flexor and extensor posturing, and abnormalities of the pupillary and oculocephalic reflexes are also poor prognostic signs and may reflect brainstem encephalitis with or without transtentorial herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/18,21\">",
"     18,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The white blood cell count is moderately elevated in most patients, and hyponatremia may be observed due to the syndrome of inappropriate anti-diuretic hormone secretion (SIADH). Thrombocytopenia, mild anemia, and elevated hepatic enzymes may also occur but are relatively non-specific laboratory features.",
"   </p>",
"   <p>",
"    The cerebrospinal fluid (CSF) opening pressure is elevated in about 50 percent of patients. CSF findings are typically a mild to moderate pleocytosis of 10 to several hundred white blood",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    with lymphocytic predominance, slightly elevated protein, and normal CSF to plasma glucose ratio. Early in disease, there may be no pleocytosis, or neutrophils may predominate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) is more sensitive than computed tomography (CT) scanning for detecting JEV-associated abnormalities such as changes in the thalamus, basal ganglia, midbrain, pons, and medulla [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Thalamic lesions are the most commonly described abnormality; although these can be highly specific for JE in the appropriate clinical context, they are not a very sensitive marker of JE (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65410 \" href=\"UTD.htm?14/6/14436\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EEG abnormalities may include theta and delta coma, burst suppression, epileptiform activity, and occasionally alpha coma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;JE is diagnosed serologically by detection of JEV-specific IgM antibodies in CSF or serum by an enzyme-linked immunosorbent assay (ELISA). The presence of JEV-specific IgM antibodies in CSF confirms recent central nervous system infection. IgM antibody in serum is suggestive of JE but could indicate asymptomatic infection or recent JEV vaccination.",
"   </p>",
"   <p>",
"    On admission to hospital, CSF antibodies are detectable in 70 to 90 percent of JE patients; JEV IgM is detectable in most CSF samples collected five to eight days after symptom onset. On admission to hospital, serum antibodies are detectable in about 60 to 70 percent of patients; serum antibodies are detectable in nearly all serum samples collected at least nine days after symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. If JE is suspected and acute samples are negative, a convalescent serum sample should be collected.",
"   </p>",
"   <p>",
"    Important considerations for interpretation of serology results include vaccination history, date of onset of symptoms, and information regarding other flaviviruses known to circulate in the geographical area that may cross-react in serologic assays (such as dengue, Murray Valley encephalitis, or West Nile viruses). As serodiagnosis of flaviviral infections is not straightforward and cross-reactivity is common, samples positive by ELISA should be referred to a reference laboratory for confirmatory plaque reduction neutralization testing (PRNT).",
"   </p>",
"   <p>",
"    United States healthcare providers should contact their state or local health department or the Centers for Disease Control and Prevention's (CDC) Division of Vector-Borne Diseases in Colorado for assistance with diagnostic testing (Telephone: 970-221-6400).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virus isolation or detection of viral RNA with a nucleic acid amplification test (NAAT) can provide a definitive diagnosis, but positive results from CSF or blood are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/18,29,30\">",
"     18,29,30",
"    </a>",
"    ]. Because humans have low levels of transient viremia and high levels of neutralizing antibodies by the time distinctive clinical symptoms are recognized, virus isolation and NAATs are insensitive for the detection of JEV or JE viral RNA in blood or CSF. JEV isolates have been obtained post mortem from brain tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of JE includes other viral encephalitides, other central nervous system infections,",
"    <span class=\"nowrap\">",
"     para/post",
"    </span>",
"    infectious causes, and non-infectious diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/21,31\">",
"     21,31",
"    </a>",
"    ]. Domestic arboviral infections should be considered if the patient could have been exposed to local arboviruses during the incubation period. In the United States, this may include La Crosse, St. Louis encephalitis, Eastern equine encephalitis, Western equine encephalitis, or Powassan viruses, among other arboviruses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/32\">",
"     32",
"    </a>",
"    ]. (See related topics).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of Japanese encephalitis (JE) consists of supportive care with emphasis on control of intracranial pressure, maintenance of adequate cerebral perfusion pressure, seizure control, and prevention of secondary complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no specific antiviral treatment for JE. A randomized, placebo-controlled trial of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in 153 Indian children did not show any difference in outcome between the treatment and control groups [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/34\">",
"     34",
"    </a>",
"    ]. Corticosteroids and interferon alpha-2a did not improve outcome in controlled clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Work is ongoing to investigate potential other antiviral agents [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality among hospitalized patients is about 20 to 30 percent. Some deaths come after a short, fulminant course while others occur after a prolonged period of coma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among Japanese encephalitis (JE) survivors, long-term sequelae occur in at least 30 to 50 percent. Although the clinical condition of many JE patients improves after hospital discharge, deterioration in the months following acute illness may be observed in about 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/15\">",
"     15",
"    </a>",
"    ]. The most common sequelae are upper and lower motor neuron weakness and cerebellar and extrapyramidal signs. Severe cognitive or language impairment, psychiatric problems, and recurrent seizures also occur. Among patients who appear to have recovered well, subtle sequelae such as learning or behavioral problems may be observed in about 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is limited information on Japanese encephalitis virus (JEV) infection in pregnancy. In India, four miscarriages were reported among nine infected pregnant women; all of the women were in the first or second trimester of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. JEV was isolated from one of the four aborted fetuses, suggesting that intrauterine transmission of JEV can occur.",
"   </p>",
"   <p>",
"    Infection with JEV is thought to produce lifelong immunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Personal protective measures to prevent mosquito bites are important to reduce the risk of Japanese encephalitis (JE) among travelers to endemic regions. In addition, JE vaccine provides substantial additional protection for travelers to high risk settings (based on location, duration, season, and activities) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Personal protective measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measures include using insect repellent, permethrin-impregnated clothing, staying in screened or air-conditioned rooms or sleeping under a bed net. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=see_link\">",
"     \"Prevention of arthropod and insect bites: Repellents and other measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Whom to vaccinate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding the use of Japanese encephalitis virus (JEV) vaccine must weigh several factors. JE is a severe disease, there is no specific treatment, and outcome is often poor. However, vaccination is associated with risk of adverse events (as well as expense), and the overall risk of travel-associated JE disease is very low. In June 2009 the Advisory Committee on Immunization Practices (ACIP) approved revised recommendations for the use of JE vaccine in travelers; these are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef54113 \" href=\"UTD.htm?14/33/14876\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     JE vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;One JE vaccine is available in the United States: an inactivated Vero cell culture-derived vaccine (JE-VC; IXIARO) (",
"    <a class=\"graphic graphic_table graphicRef78205 \" href=\"UTD.htm?42/61/43995\">",
"     table 2",
"    </a>",
"    ). JE-VC was licensed in 2009 for use in individuals &ge;17 years; clinical trials to enable licensure in children are ongoing. An inactivated mouse brain-derived vaccine (JE-MB; JE-VAX) was used in the United States for almost 20 years following its licensure in 1992, but is no longer available.",
"   </p>",
"   <p>",
"    Other JE vaccines are manufactured and used in other countries but are not licensed for use in the United States. These include a live attenuated SA 14-14-2 vaccine manufactured in China, inactivated Vero cell culture-derived vaccines manufactured in Japan, mouse brain-derived inactivated vaccines manufactured in several Asian countries, and a live, attenuated chimeric virus vaccine licensed in Australia. The recommended number of doses and schedule varies by vaccine and country.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347394494\">",
"    <span class=\"h4\">",
"     JE-VC",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347394509\">",
"    <span class=\"h5\">",
"     Immunogenicity and safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no efficacy data for JE-VC. The vaccine was licensed on the basis of its ability to induce Japanese encephalitis virus (JEV) neutralizing antibodies as a surrogate for protection and safety evaluations in approximately 5000 adults [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/3\">",
"     3",
"    </a>",
"    ]. JEV neutralizing antibody levels measured by plaque reduction neutralization test are thought to be a reliable surrogate for efficacy.",
"   </p>",
"   <p>",
"    In a non-inferiority immunogenicity study comparing JE-VC (two dose schedule; 365 adults) with JE-MB (three dose schedule; 370 adults), seroconversion rates at 28 days after the last dose were comparable (96 versus 94 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies evaluating subjects receiving JE-VC or placebo adjuvant have described comparable rates of local and systemic reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In a study evaluating 2650 subjects who received JE-VC or placebo adjuvant, the frequency of injection site reaction was similar in both groups (about 55 percent overall; 3 percent severe) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Pain and tenderness were the most common reactions. Overall, about 60 percent of subjects reported a systemic adverse event; headache, myalgias, fatigue, and an influenza-like illness were each reported at a rate of &gt;10 percent. The rates of serious adverse events following immunization were also similar in the vaccine and the placebo groups (0.5 and 0.9 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347394526\">",
"    <span class=\"h5\">",
"     Dosage and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended primary immunization schedule is two doses administered intramuscularly on days 0 and 28. The dose is 0.5 mL for persons &ge;17 years of age, and the two-dose series should be completed at least one week prior to travel.",
"   </p>",
"   <p>",
"    The vaccine is not currently licensed for use in children. One pediatric clinical trial has been completed in 60 children aged 1 to 3 years in India (44 children received JE-VC) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/45\">",
"     45",
"    </a>",
"    ]. Additional data will be available in future from a study in approximately 1900 children aged 2 months to 17 years in the Philippines, and a bridging study in the United States and other non-endemic countries with a targeted enrollment of approximately 100 children. Options for obtaining Japanese encephalitis (JE) vaccine for United States children traveling to at-risk areas include enrolling in the ongoing JE-VC pediatric clinical trial at one of five United States sites, using JE-VC off-label, or receiving a JE vaccine at an international travelers&rsquo; health clinic in Asia. More information regarding these options is available from the CDC [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A severe allergic reaction after a previous dose of JE-VC is a contraindication to subsequent administration. JE-VC contains",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/9/11413?source=see_link\">",
"     protamine sulfate",
"    </a>",
"    , which is known to cause hypersensitivity reactions in some individuals; it does not contain gelatin or murine proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/47\">",
"     47",
"    </a>",
"    ]. The risk of hypersensitivity or neurologic adverse events with JE-VC is probably lower than that with JE-MB, although the possibility of rare adverse events cannot be excluded. Limited data on the use of JE-VC in individuals &ge;65 years suggest safety and immunogenicity are similar to those among younger subjects, but further data are needed. No studies of JE-VC in pregnant women have been conducted. Therefore, administration of JE-VC to pregnant women usually should be deferred. However, pregnant women who must travel to an area where risk for JEV infection is high should be vaccinated when the theoretical risk for immunization is outweighed by the risk for infection.",
"   </p>",
"   <p>",
"    If the primary series of JE-VC was administered &gt;1 year previously, a booster dose may be given before potential JE virus exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/48\">",
"     48",
"    </a>",
"    ]. Two studies have investigated the use of JE-VC as a booster dose after a primary series with JE-MB; one study was performed among United States military personnel and the other was conducted at two European travel clinics [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5208/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Both studies demonstrated that in individuals who previously received at least a primary series of JE-MB, a single dose of JE-VC adequately boosted neutralizing antibody levels and provided at least short-term protection. Both studies measured antibody responses at four to eight weeks after the booster dose; therefore, additional studies are needed to determine the duration of protection following a single dose of JE-VC in prior recipients of JE-MB. In the United States, adults who have received JE-MB previously and require further vaccination against JE virus should receive a two dose primary series of JE-VC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Japanese encephalitis virus (JEV), a mosquito-borne flavivirus, is the most important cause of viral encephalitis in Asia based on its frequency and severity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      About 68,000 cases of Japanese encephalitis (JE) are estimated to occur each year. However for travelers the risk is low; since a JE vaccine was licensed in the United States in 1992, only seven cases of JE have been reported among United States travelers. Fewer than 1 percent of JEV infections results in symptomatic neuroinvasive disease. However, when neurological disease does occur, it is usually a very severe disease with a high case fatality rate and neurological sequelae in 30 to 50 percent of survivors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In endemic areas, JE typically affects children &lt;15 years of age; by early adulthood the majority of the population has protective immunity following natural exposure to JEV as a result of ongoing environmental transmission Among immunologically na&iuml;ve travelers visiting endemic regions, the disease can affect individuals at any age. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      JEV is transmitted in an enzootic cycle involving mosquitoes and vertebrate amplifying hosts, primarily pigs and wading birds. Humans are incidental and dead end hosts in the JEV transmission cycle, as they do not develop sufficiently high viremia to infect feeding mosquitoes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most commonly recognized clinical presentation of JEV infection is acute encephalitis. Milder forms of disease such as aseptic meningitis or non-specific febrile illness with headache also occur. Seizures (usually generalized tonic-clonic) are very common, especially among children. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      JE is diagnosed serologically by detection of JEV-specific IgM antibody in cerebrospinal fluid (CSF) or serum by an enzyme-linked immunosorbent assay (ELISA). The presence of JEV-specific IgM antibodies in CSF confirms recent central nervous system infection. IgM antibody in serum is suggestive of JE but could indicate asymptomatic infection or recent JE vaccination. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Serology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific antiviral treatment for JE. Treatment consists of supportive care with emphasis on control of intracranial pressure, maintenance of adequate cerebral perfusion pressure, seizure control, and prevention of secondary complications. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Precautions to reduce the risk of JE among travelers to endemic regions include personal protective measures to prevent mosquito bites. For some travelers who will be in a high risk setting (based on location, duration, season, and activities), JE vaccine may further reduce the risk of infection (",
"      <a class=\"graphic graphic_table graphicRef54113 \" href=\"UTD.htm?14/33/14876\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One JE vaccine is available in the United States: an inactivated Vero cell culture-derived vaccine (JE-VC; IXIARO). JE-VC is licensed for use in persons aged &ge;17 years; clinical trials to enable licensure in children are ongoing. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'JE vaccines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/1\">",
"      Halstead SB, Jacobson J. Japanese encephalitis. Adv Virus Res 2003; 61:103.",
"     </a>",
"    </li>",
"    <li>",
"     Mackenzie JS, Williams DT, Smith DW. Japanese encephalitis virus: The geographic distribution, incidence, and spread of a virus with a propensity to emerge in new areas. In: Emerging Viruses in Human Populations, Tabor E (Ed), Elsevier, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/3\">",
"      Fischer M, Lindsey N, Staples JE, et al. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/4\">",
"      Centers for Disease Control and Prevention (CDC). Japanese encephalitis in two children--United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/5\">",
"      Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am J Trop Med Hyg 2010; 82:930.",
"     </a>",
"    </li>",
"    <li>",
"     Halstead S, Jacobson J. Japanese encephalitis vaccines. In: Vaccines, 5th ed, Plotkin S, Orenstein W, Offit P (Eds), Saunders Elsevier, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/7\">",
"      Endy TP, Nisalak A. Japanese encephalitis virus: ecology and epidemiology. Curr Top Microbiol Immunol 2002; 267:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/8\">",
"      Arai S, Matsunaga Y, Takasaki T, et al. Japanese encephalitis: surveillance and elimination effort in Japan from 1982 to 2004. Jpn J Infect Dis 2008; 61:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/9\">",
"      Vaughn DW, Hoke CH Jr. The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol Rev 1992; 14:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/10\">",
"      Ompusunggu S, Hills SL, Maha MS, et al. Confirmation of Japanese encephalitis as an endemic human disease through sentinel surveillance in Indonesia. Am J Trop Med Hyg 2008; 79:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/11\">",
"      Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 2000; 18 Suppl 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/12\">",
"      Wu YC, Huang YS, Chien LJ, et al. The epidemiology of Japanese encephalitis on Taiwan during 1966-1997. Am J Trop Med Hyg 1999; 61:78.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. CDC Heath Information for International Travel 2012. US Department of Health and Human Services, Public Health Service, Atlanta, GA 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/14\">",
"      van den Hurk AF, Ritchie SA, Mackenzie JS. Ecology and geographical expansion of Japanese encephalitis virus. Annu Rev Entomol 2009; 54:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/15\">",
"      Ooi MH, Lewthwaite P, Lai BF, et al. The epidemiology, clinical features, and long-term prognosis of Japanese encephalitis in central sarawak, malaysia, 1997-2005. Clin Infect Dis 2008; 47:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/16\">",
"      Solomon T, Dung NM, Kneen R, et al. Japanese encephalitis. J Neurol Neurosurg Psychiatry 2000; 68:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/17\">",
"      LINCOLN AF, SIVERTSON SE. Acute phase of Japanese B encephalitis; two hundred and one cases in American soldiers, Korea, 1950. J Am Med Assoc 1952; 150:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/18\">",
"      Solomon T, Dung NM, Kneen R, et al. Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain 2002; 125:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/19\">",
"      Solomon T, Kneen R, Dung NM, et al. Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet 1998; 351:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/20\">",
"      Chung CC, Lee SS, Chen YS, et al. Acute flaccid paralysis as an unusual presenting symptom of Japanese encephalitis: a case report and review of the literature. Infection 2007; 35:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/21\">",
"      Solomon T. Flavivirus encephalitis. N Engl J Med 2004; 351:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/22\">",
"      Maschke M, Kastrup O, Forsting M, Diener HC. Update on neuroimaging in infectious central nervous system disease. Curr Opin Neurol 2004; 17:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/23\">",
"      Wang HS. Comparison of magnetic resonance imaging abnormalities in Japanese encephalitis and acute necrotizing encephalopathy of childhood. Arch Neurol 2004; 61:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/24\">",
"      Dung NM, Turtle L, Chong WK, et al. An evaluation of the usefulness of neuroimaging for the diagnosis of Japanese encephalitis. J Neurol 2009; 256:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/25\">",
"      Solomon T, Thao TT, Lewthwaite P, et al. A cohort study to assess the new WHO Japanese encephalitis surveillance standards. Bull World Health Organ 2008; 86:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/26\">",
"      Kari K, Liu W, Gautama K, et al. A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia. BMC Med 2006; 4:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/27\">",
"      Burke DS, Lorsomrudee W, Leake CJ, et al. Fatal outcome in Japanese encephalitis. Am J Trop Med Hyg 1985; 34:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/28\">",
"      Chanama S, Sukprasert W, Sa-ngasang A, et al. Detection of Japanese encephalitis (JE) virus-specific IgM in cerebrospinal fluid and serum samples from JE patients. Jpn J Infect Dis 2005; 58:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/29\">",
"      Swami R, Ratho RK, Mishra B, Singh MP. Usefulness of RT-PCR for the diagnosis of Japanese encephalitis in clinical samples. Scand J Infect Dis 2008; 40:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/30\">",
"      Kuwayama M, Ito M, Takao S, et al. Japanese encephalitis virus in meningitis patients, Japan. Emerg Infect Dis 2005; 11:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/31\">",
"      Solomon T, Hart IJ, Beeching NJ. Viral encephalitis: a clinician's guide. Pract Neurol 2007; 7:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/32\">",
"      Reimann CA, Hayes EB, DiGuiseppi C, et al. Epidemiology of neuroinvasive arboviral disease in the United States, 1999-2007. Am J Trop Med Hyg 2008; 79:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/33\">",
"      Tiroumourougane SV, Raghava P, Srinivasan S. Japanese viral encephalitis. Postgrad Med J 2002; 78:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/34\">",
"      Kumar R, Tripathi P, Baranwal M, et al. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Clin Infect Dis 2009; 48:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/35\">",
"      Hoke CH Jr, Vaughn DW, Nisalak A, et al. Effect of high-dose dexamethasone on the outcome of acute encephalitis due to Japanese encephalitis virus. J Infect Dis 1992; 165:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/36\">",
"      Solomon T, Dung NM, Wills B, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 2003; 361:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/37\">",
"      Gould EA, Solomon T, Mackenzie JS. Does antiviral therapy have a role in the control of Japanese encephalitis? Antiviral Res 2008; 78:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/38\">",
"      Caramello P, Canta F, Balbiano R, et al. Role of intravenous immunoglobulin administration in Japanese encephalitis. Clin Infect Dis 2006; 43:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/39\">",
"      Chaturvedi UC, Mathur A, Chandra A, et al. Transplacental infection with Japanese encephalitis virus. J Infect Dis 1980; 141:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/40\">",
"      Mathur A, Tandon HO, Mathur KR, et al. Japanese encephalitis virus infection during pregnancy. Indian J Med Res 1985; 81:9.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/vaccines/recs/provisional/default.htm#acip (Accessed on August 26, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/42\">",
"      Tauber E, Kollaritsch H, Korinek M, et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007; 370:1847.",
"     </a>",
"    </li>",
"    <li>",
"     Japanese Encephalitis Vaccine, Inactivated, Adsorbed (IXIARO). Package insert (commercial). file://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm179132.htm (Accessed on May 19, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/44\">",
"      Tauber E, Kollaritsch H, von Sonnenburg F, et al. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008; 198:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/45\">",
"      Kaltenb&ouml;ck A, Dubischar-Kastner K, Schuller E, et al. Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010; 28:834.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/ncidod/dvbid/jencephalitis/children.htm (Accessed on June 07, 2011).",
"    </li>",
"    <li>",
"     FDA. Product approval information [package insert]. Ixiaro (Japanese encephalitis virus vaccine inactivated). Intercell Biomedical, Livingston, United Kingdom. file://www.fda.gov/cber/label/ixiarocommercialLB.pdf (Accessed on July 31, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/48\">",
"      Centers for Disease Control and Prevention (CDC). Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011. MMWR Morb Mortal Wkly Rep 2011; 60:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/49\">",
"      Erra EO, Askling HH, Rombo L, et al. A single dose of vero cell-derived Japanese encephalitis (JE) vaccine (Ixiaro) effectively boosts immunity in travelers primed with mouse brain-derived JE vaccines. Clin Infect Dis 2012; 55:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5208/abstract/50\">",
"      Woolpert T, Staples JE, Faix DJ, et al. Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine. Vaccine 2012; 30:3090.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3034 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5208=[""].join("\n");
var outline_f5_5_5208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Personal protective measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Whom to vaccinate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - JE vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H347394494\">",
"      JE-VC",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H347394509\">",
"      - Immunogenicity and safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H347394526\">",
"      - Dosage and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3034\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3034|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/6/14436\" title=\"diagnostic image 1\">",
"      JE MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3034|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/33/23063\" title=\"figure 1\">",
"      JE map distribution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3034|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/33/14876\" title=\"table 1\">",
"      JE vaccine recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/61/43995\" title=\"table 2\">",
"      Components and administration of IXIARO",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=related_link\">",
"      Prevention of arthropod and insect bites: Repellents and other measures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_5_5209="Variant sickle cell syndromes";
var content_f5_5_5209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Variant sickle cell syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/5/5209/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/5/5209/contributors\">",
"     Elliott P Vichinsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/5/5209/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/5/5209/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/5/5209/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/5/5209/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/5/5209/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaso-occlusive phenomena and hemolytic anemia are the clinical hallmarks of sickle cell disease (SCD). Vaso-occlusion results in recurrent painful episodes and a variety of serious organ system complications that can lead to life-long disabilities and even death.",
"   </p>",
"   <p>",
"    Hemoglobin S results from the substitution of a valine for glutamic acid as the sixth amino acid of the beta-globin chain, which produces a hemoglobin tetramer",
"    <span class=\"nowrap\">",
"     (alpha2/betaS2)",
"    </span>",
"    that is poorly soluble when deoxygenated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/1\">",
"     1",
"    </a>",
"    ]. The polymerization of deoxy hemoglobin (Hb) S is essential to vaso-occlusive phenomena [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/1\">",
"     1",
"    </a>",
"    ]. The polymer assumes the form of an elongated rope-like fiber which usually aligns with other fibers, resulting in distortion of the affected red blood cell into the classic crescent or sickle shape and a marked decrease in red cell deformability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=see_link\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, polymerization alone does not account for the pathophysiology of SCD. Subsequent changes in red cell membrane structure and function, disordered cell volume control, and increased adherence to vascular endothelium also play an important role [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disease manifestations are most severe in patients with homozygous Hb SS. There are a variety of other sickle cell syndromes that result from inheritance of the sickle cell gene in compound heterozygosity with other mutant beta globin genes, leading to disorders such as Hb SC disease and sickle cell-beta thalassemia. The clinical characteristic of these variant sickle cell syndromes will be reviewed here. The clinical manifestations, diagnosis, and treatment of homozygous SCD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link\">",
"     \"Diagnosis of sickle cell syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sickle cell trait (Hb AS) in which one sickle cell beta-globin gene has been inherited along with a normal beta-globin gene (ie,",
"    <span class=\"nowrap\">",
"     alpha2/betaS1beta1),",
"    </span>",
"    is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13960?source=see_link\">",
"     \"Sickle cell trait\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HB SC DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene for Hb C (a2bC2[6Glu-&gt;Lys]) is approximately one-fourth as common among African-Americans as the sickle cell gene [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/3\">",
"     3",
"    </a>",
"    ]. Although oxygenated Hb C forms crystals, Hb C does not participate in polymerization with deoxy Hb S [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, the presence of Hb C within the cell leads to enhanced and sustained potassium and chloride cotransport. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=see_link\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\"",
"    </a>",
"    .) The loss of K+ produces red cell dehydration and an increase in the intraerythrocytic concentration of Hb S to levels that may support polymerization, sickling, and clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. In vitro studies have found that, at the same total Hb concentration, a 50:50 Hb S and Hb C mixture undergoes polymerization 15 times more rapidly than a 40:60 Hb S and Hb A mixture; this difference is presumably due to the higher Hb S concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect is that compound heterozygosity for Hb S and C results in a disease that is less severe than SCD but more severe than sickle cell trait [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Anemia and reticulocytosis are frequently mild, with the majority of patients having a milder degree of anemia (hematocrit &gt;28 percent) than is usually seen in SCD. This difference is due to the longer survival of Hb SC compared with Hb SS red cells in the circulation (27 versus 17 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Splenomegaly may be the only physical finding. The predominant red cell abnormality on the peripheral smear is an abundance of target cells. Folded (Pita bread, clam-shell) cells, irreversibly sickled cells, \"billiard ball\" cells, and crystal-containing cells also may be seen (",
"    <a class=\"graphic graphic_picture graphicRef71393 \" href=\"UTD.htm?42/19/43318\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/11\">",
"     11",
"    </a>",
"    ]. Hemoglobin electrophoresis shows equal amounts of Hb S and Hb C (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68806 \" href=\"UTD.htm?8/51/9023\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with Hb SC disease are at risk for the same life-threatening complications as Hb SS but at a decreased frequency. A small subset of Hb SC patients have a clinical phenotype similar to Hb SS. Overall, the clinical severity of Hb SC is milder, as indicated from the Cooperative Study of Sickle Cell Disease, which compared Hb SC disease with Hb SS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 50 percent lower rate of acute painful episodes (0.4 versus 0.8 per year) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A lower risk of silent infarcts (3 versus 17 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/13\">",
"       13",
"      </a>",
"      ] and of having a stroke (2 versus 11 percent incidence of a first stroke by age 20) (",
"      <a class=\"graphic graphic_figure graphicRef61397 \" href=\"UTD.htm?40/31/41469\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A lower rate of focal segmental glomerulosclerosis (2.4 versus 4.2 percent in one study) with a later onset of progressive renal failure (50 versus 23 years old at diagnosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A lower incidence of fatal bacterial infection in young children [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A very low rate of leg ulcers [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/18\">",
"       18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Later development of osteonecrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A lesser delay in growth and sexual development [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A two decade increase in life expectancy (64 versus 45 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A more benign course when pregnant. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H33#H33\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Pregnancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A higher incidence of peripheral retinopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/22\">",
"       22",
"      </a>",
"      ], thought to be related to the higher hematocrit in this disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Functional asplenia occurs in many patients with Hb SC disease (45 percent in subjects over age 25 in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/23\">",
"     23",
"    </a>",
"    ]. However, it does not occur prior to age four and routine administration of prophylactic penicillin may not be necessary in infants and young children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The persistent splenic function means that splenic infarction and splenic sequestration crisis, which primarily occur in young children with SCD, can occur at all ages in Hb SC disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Acute severe anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Hb SC disease is straightforward, as nearly equal amounts of Hb S and Hb C are detected on hemoglobin electrophoresis (",
"    <a class=\"graphic graphic_table graphicRef64715 \" href=\"UTD.htm?17/56/18316\">",
"     table 1",
"    </a>",
"    ). It is important to remember than on cellulose acetate electrophoresis, hemoglobin C may migrate with hemoglobins E, O-Arab, and C-Harlem. Target cells predominate on the peripheral blood smear and sickled cells are relatively uncommon (",
"    <a class=\"graphic graphic_picture graphicRef71393 \" href=\"UTD.htm?42/19/43318\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link\">",
"     \"Diagnosis of sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SICKLE-BETA THALASSEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thalassemia refers to a spectrum of diseases characterized by reduced or absent production of one or more globin chains. Beta thalassemia is due to impaired production of beta globin chains, which leads to a relative excess of alpha globin chains. These excess alpha globin chains are unstable, incapable of forming soluble tetramers on their own, and precipitate within the cell, leading to a variety of clinical manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link\">",
"     \"Pathophysiology of beta thalassemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The gene frequency of beta thalassemia among African-Americans is 0.004, one-tenth that of the sickle cell gene [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result, the prevalence of compound heterozygous sickle cell-beta thalassemia is one-tenth that of sickle cell anemia in this population. In addition to the African-American population, people of Hispanic descent are at risk for sickle-beta thalassemia. In California, 12.5 percent of newborns with sickle-beta thalassemia have Hispanic origin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/25\">",
"     25",
"    </a>",
"    ]. Sickle cell-beta thalassemia is divided into sickle cell-beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia and sickle cell-beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia, based upon the absence or presence, respectively, of reduced amounts of beta globin and therefore of Hb A [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Most beta thalassemia mutations among African-Americans result in beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia. The percentage of Hb A produced varies from 5 to 30 percent, depending upon the molecular defect of the mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eighty percent of African-American beta thalassemia mutations are due to promoter region mutations that result in a mild phenotype in which Hb A accounts for 18 to 25 percent of total hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Compound heterozygous sickle cell-beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia, which results in the production of no normal beta chains and therefore no Hb A, occurs infrequently in the African-American population, but more commonly in the Greek and Mediterranean regions.",
"   </p>",
"   <p>",
"    The hematologic and clinical severity of sickle cell-beta thalassemia is an inverse function of the quantity of Hb A [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], although patients with sickle cell-beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia may have less severe disease than those with homozygous SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/31\">",
"     31",
"    </a>",
"    ]. However, the genotype-phenotype correlations are variable, and a severe clinical course can be seen in patients with a milder beta thalassemic mutation.",
"   </p>",
"   <p>",
"    The red cells are hypochromic and microcytic, and more irreversibly sickled cells are seen in the peripheral blood smear in sickle cell-beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia than in sickle cell-beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia. One study compared the incidence of other factors in 27 patients with sickle cell-beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia and 28 patients with sickle cell-beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/32\">",
"     32",
"    </a>",
"    ]. The lesser severity of sickle cell-beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia was illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Threefold higher incidence of incidental diagnosis (26 versus 9 percent)",
"     </li>",
"     <li>",
"      Later mean age of presentation (8.2 versus 3.2 years)",
"     </li>",
"     <li>",
"      Less frequent leg ulcers (8 versus 23 percent)",
"     </li>",
"     <li>",
"      Less frequent episodes of acute chest syndrome (14 versus 24 percent); this approximately 50 percent reduction in painful episodes has been noted in other reports [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Less frequent priapism (0 versus 4 patients)",
"     </li>",
"     <li>",
"      Less frequent aplastic crises (0 versus 2 patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Splenomegaly occurred in approximately one-third of both groups. There was a higher incidence of proliferative retinopathy in sickle cell-beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia (18 versus 10 percent), consistent with the notion that those sickle cell syndromes having higher hematocrits and blood viscosity are more likely to be associated with ocular complications. Both forms of sickle cell-beta thalassemia are associated with a marked reduction in the incidence of stroke (",
"    <a class=\"graphic graphic_figure graphicRef61397 \" href=\"UTD.htm?40/31/41469\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/14\">",
"     14",
"    </a>",
"    ], although some subjects with no history of clinical stroke have demonstrated silent infarction on magnetic resonance imaging as well as abnormal transcranial Doppler studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another series evaluated 2115 patients with homozygous SCD, Hb SC disease, sickle cell-beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia, or sickle cell-beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/20\">",
"     20",
"    </a>",
"    ]. The patients with SCD or sickle cell-beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia were consistently smaller and less sexually developed than those with sickle cell-beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia.",
"   </p>",
"   <p>",
"    Ischemic cardiac disease can occur in patients with sickle cell syndromes including sickle cell-beta thalassemia. In general, this is due to small vessel disease and not coronary artery occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. It may also be associated with a cardiovascular autonomic dysfunction. These findings are well documented in Greek studies of sickle cell-beta thalassemia patients who had angina and myocardial infarction with normal coronary arteries and no cardiac risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/37\">",
"     37",
"    </a>",
"    ]. In one study, for example, 8 of 30 Greek patients (mean age 37 &plusmn; 10 years, mean percent hemoglobin A 6 percent) with sickle cell-beta thalassemia developed scintigraphic evidence of myocardial perfusion defects on exercise testing in the presence of angiographically-proven normal coronary arteries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from electrophoresis or thin-layer isoelectric focusing are similar in SCD and sickle cell-beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia, as nearly all the hemoglobin consists of Hb S, and there is no Hb A present. Differences in the Hb F and Hb A2 levels may be useful in distinguishing these syndromes (",
"    <a class=\"graphic graphic_table graphicRef64715 \" href=\"UTD.htm?17/56/18316\">",
"     table 1",
"    </a>",
"    ). However, these levels may overlap among sickle variants. In addition, the presence of microcytosis or of one parent without sickle cell trait are useful indicators of sickle cell-beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia.",
"   </p>",
"   <p>",
"    Sickle cell-beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia and sickle cell trait both have substantial amounts of Hb A and Hb S. Sickle cell trait is not associated with anemia or microcytosis and, as noted above, has a Hb A fraction that exceeds 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/38\">",
"     38",
"    </a>",
"    ]; sickle cell-beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia is associated with anemia, microcytosis, and a Hb A fraction that ranges between 5 and 30 percent (",
"    <a class=\"graphic graphic_table graphicRef64715 \" href=\"UTD.htm?17/56/18316\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=see_link\">",
"     \"Diagnosis of sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the neonatal period, diagnosing sickle beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia may be more difficult. Since HbF is the predominant hemoglobin, the low levels of HbS and HbA present may make it unclear which one is in greater amount. In addition, neonates with sickle beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia may have so little HbA present that the diagnosis of sickle beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia is given. Therefore, family studies and more definitive testing are indicated in questionable cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SICKLE-ALPHA THALASSEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha thalassemia results from impaired production of alpha globin chains, which leads to a relative excess of beta globin chains. The toxicity of excess normal beta globin chains on the red cell membrane skeleton appears to be less than that of the excess partially oxidized alpha globin chains in beta thalassemia. This may be extrapolated to beta S chains to explain why the clinical manifestations are generally less severe in sickle cell-alpha thalassemia compared with sickle cell-beta thalassemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=see_link\">",
"     \"Pathophysiology of alpha thalassemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The gene frequency of the alpha thalassemia-2 haplotype (-a) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/39,40\">",
"     39,40",
"    </a>",
"    ] among African-Americans is 0.16 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/41\">",
"     41",
"    </a>",
"    ]. Thus, one in three is a silent carrier with the genotype",
"    <span class=\"nowrap\">",
"     (-a/aa)",
"    </span>",
"    and 2 percent have alpha thalassemia trait due to homozygous alpha thalassemia-2, with the genotype",
"    <span class=\"nowrap\">",
"     (-a/-a)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/41\">",
"     41",
"    </a>",
"    ]. Concurrent alpha thalassemia has a beneficial effect upon the pathobiology of sickle red cells because unbalanced globin chain synthesis leads to a deficiency in the amount of hemoglobin per cell. The number of dense cells is lower, and the red cell deformability is better, in patients with concurrent alpha thalassemia.",
"   </p>",
"   <p>",
"    Due to the powerful effect of Hb S concentration upon Hb S polymerization, anemia is significantly milder in subjects with SCD and the deletion of either one",
"    <span class=\"nowrap\">",
"     (-a/aa)",
"    </span>",
"    or two",
"    <span class=\"nowrap\">",
"     (-a/-a)",
"    </span>",
"    alpha globin genes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/42-46\">",
"     42-46",
"    </a>",
"    ]. In one series, for example, the hemoglobin concentration was 9.8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in patients with SCD and the",
"    <span class=\"nowrap\">",
"     (-a/aa)",
"    </span>",
"    genotype compared with 7.9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in those with SCD alone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/42\">",
"     42",
"    </a>",
"    ]. These subjects have reduced hemolysis that is not demonstrable until approximately seven years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to milder anemia, sickle cell-alpha thalassemia is associated with fewer reticulocytes and sickled cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/42-44,47\">",
"     42-44,47",
"    </a>",
"    ]. The peripheral blood smear contains less polychromasia and fewer sickle forms and more hypochromia and microcytosis, commensurate with the number of alpha globin genes deleted. Hb A2 levels are increased according to the number of alpha globin gene deletions, while Hb F levels are not consistently affected [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/42-44,48\">",
"     42-44,48",
"    </a>",
"    ]. The prediction of increased affinity of alpha for gamma chains, resulting in higher levels of Hb F when alpha chains are limiting, is not consistently realized in patients with sickle cell-alpha thalassemia, apparently due to the selective survival of alpha thalassemic sickle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the improvement in anemia, the clinical effects of the interaction between SCD and alpha thalassemia are variable, due in part to the higher hemoglobin concentration and blood viscosity. While the overall clinical phenotype may be improved, it is unclear whether alpha thalassemia increases survival in patients with sickle cell anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=see_link\">",
"     \"Clinical variability in sickle cell anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of acute chest syndrome was decreased in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/43\">",
"       43",
"      </a>",
"      ] and unchanged in another [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/44\">",
"       44",
"      </a>",
"      ]. In a third report from the Cooperative Study of Sickle Cell disease, concurrent alpha thalassemia had no effect on the incidence of acute painful episodes apart from its association with higher hemoglobin concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is a reduced incidence of leg ulcers (more in patients with two versus three alpha globin genes) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/18,43\">",
"       18,43",
"      </a>",
"      ], but an increased incidence of osteonecrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/19,51\">",
"       19,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      More recent studies have found that the frequency of retinal vessel closure was reduced, but not that of proliferative retinopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best data on life expectancy come from the Cooperative Study of Sickle Cell disease, which found an increased mortality rate associated with higher hemoglobin levels after the age of 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SICKLE-HEREDITARY PERSISTENCE OF FETAL HB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic switch from the production of fetal hemoglobin (Hb F: alpha",
"    <span class=\"nowrap\">",
"     2/gamma",
"    </span>",
"    2) to the adult form of hemoglobin (Hb A: alpha",
"    <span class=\"nowrap\">",
"     2/beta",
"    </span>",
"    2) is usually accomplished by two years of age, resulting in a normal adult level of Hb F of less than 1 percent. However, increased levels of Hb F can ameliorate the clinical course of disorders of beta globin gene expression, such as SCD and beta thalassemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=see_link\">",
"     \"Clinical variability in sickle cell anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Variations in the Hb F percentage account for much of the clinical heterogeneity observed in patients with SCD; the Hb F level is an important prognostic factor for both sickle cell pain and mortality. A Hb F level of 10 to 20 percent has been suggested as a threshold for diminished clinical severity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/53\">",
"     53",
"    </a>",
"    ], although some studies have suggested that any increment in Hb F may be clinically important [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a group of disorders called hereditary persistence of fetal hemoglobin (HPFH), expression of the gamma globin gene of Hb F persists at high levels in adult erythroid cells with normal red blood cell indices and morphology. Molecular studies have identified two groups of disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pancellular forms are usually due to major deletions of the beta globin gene cluster, including the gamma gene silencers [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/54\">",
"       54",
"      </a>",
"      ]. They are characterized by clearly increased levels of Hb F in heterozygotes (15 to 35 percent).",
"     </li>",
"     <li>",
"      The heterocellular forms are characterized by modest elevations in Hb F (1 to 4 percent) distributed in an uneven fashion among the F cells. Molecular lesions include promoter mutations in the gamma globin genes and mutations distant from the beta globin cluster, including a determinant on chromosome 6q in some families [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The gene frequency of the deletional HPFH locus is 0.0005 among African-Americans, resulting in a calculated incidence of compound heterozygous sickle cell-deletional HPFH that is 1 percent that of SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/57\">",
"     57",
"    </a>",
"    ]. Sickle cell-deletional HPFH provided the first evidence that Hb F was a potent inhibitor of Hb S polymerization. Individuals with pancellular distribution of 25 percent Hb F are usually neither anemic nor do they suffer from vasoocclusive manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemoglobin electrophoresis reveals only Hb S, F, and A2, which resembles sickle cell anemia, sickle cell-beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia, and sickle cell-delta beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia. Notable differences, however, are the pancellular distribution of 15 to 35 percent Hb F, Hb A2 levels &lt;2.5 percent (in contrast to the elevated levels in beta thalassemia), and the absence of anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SICKLE-DELTA BETA(0) THALASSEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The delta beta thalassemia mutations usually are large deletions of the delta and beta globin genes. Unlike hereditary persistence of fetal hemoglobin, these mutations fail to retard the switch from fetal to adult hemoglobin production. This allows an attempted switch from the expression of gamma globin to that of the deleted delta and beta genes. The uncommon compound heterozygous condition with the sickle gene results in the presence of Hb S, F, and A2. The 15 to 25 percent Hb F is distributed in a heterocellular fashion. Anemia and reticulocytosis are mild, and clinical complications are infrequent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SICKLE-HB LEPORE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Hb Lepore gene is a crossover fusion product of the delta and beta globin genes, the product of which, in the case of Hb Lepore Boston, has the same alkaline electrophoretic mobility as Hb S [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/61\">",
"     61",
"    </a>",
"    ]. Because of the thalassemic expression of the fusion gene, individuals with simple heterozygosity for Hb Lepore Boston resemble sickle cell trait on hemoglobin electrophoresis, with only 12 percent of the mutant hemoglobin being present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9129?source=see_link&amp;anchor=H15#H15\">",
"     \"Molecular pathology of the thalassemic syndromes\", section on 'Hb Lepore'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The doubly heterozygous condition of sickle cell-Hb Lepore (Hb S-Lepore) is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/62\">",
"     62",
"    </a>",
"    ]. The peripheral smear shows microcytosis, hypochromia, and irreversibly sickled cells. Vasoocclusive complications occur and splenomegaly is common [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with this disorder resemble those with sickle cell anemia or sickle cell-beta",
"    <sup>",
"     0",
"    </sup>",
"    thalassemia electrophoretically, but have less severe anemia similar to sickle cell-beta",
"    <sup>",
"     +",
"    </sup>",
"    thalassemia. The combination of predominantly Hb S with microcytosis suggests sickle cell-beta thalassemia, but the diagnosis of Hb S Lepore is suggested by the low to low normal Hb A2 levels that result from the incapacitation of one delta globin gene by the crossover. Hb F levels vary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SICKLE-HB D DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common hemoglobin D variant, Hb D Los Angeles (beta 121 Glu-&gt;Gln, also called hemoglobin D Punjab), is caused by a glutamic acid to glutamine substitution at codon 121 of the beta globin gene [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/64\">",
"     64",
"    </a>",
"    ]. Although asymptomatic in the heterozygous form, inheritance together with an Hb S allele (Hb SD disease) can result in a severe disease with clinical manifestations similar to homozygous SCD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/65\">",
"     65",
"    </a>",
"    ]. The glutamic acid to glutamine substitution appears to support the polymerization of Hb S [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hb D Los Angeles has an electrophoretic mobility which is similar to Hb S under alkali conditions. For this reason, Hb SD disease was first reported as an unusual case of sickle cell anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/67\">",
"     67",
"    </a>",
"    ]. Hb D can be distinguished from Hb S by acid electrophoresis or isoelectric focusing. There is moderately severe hemolytic anemia and the peripheral smear shows marked anisocytosis and poikilocytosis, target cells, and irreversibly sickled cells. Some children have severe disease similar to that of sickle cell anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. However, persistent splenomegaly is more common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SICKLE-HB O ARAB DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin O Arab is another hemoglobinopathy due to a variant beta globin chain (beta 121 Glu-&gt;Lys). It was first described in an Israeli Arab family but its distribution is widespread [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sickle cell-Hb O Arab resembles Hb SC on alkaline electrophoresis, but Hb O Arab can be distinguished from Hb C by either acid electrophoresis or isoelectric focusing. Hemoglobin O-Arab may be confused with Hb C-Harlem when Hb S is also present. The syndrome is characterized by moderately severe hemolytic anemia, and the peripheral smear shows anisocytosis, poikilocytosis and irreversibly sickled cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Oxygen affinity is reduced in sickle cell-Hb O-Arab compared with sickle cell anemia.",
"   </p>",
"   <p>",
"    The clinical manifestations are severe and resemble those of homozygous sickle cell anemia. In one study of 13 patients, for example, all patients had significant sickling events including acute chest syndrome (11), recurrent painful episodes (10) nephropathy (4), aplastic crises (2), avascular necrosis (2), leg ulcers (2), and stroke (1) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SICKLE-HB E DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hb E (beta 26, Glu-&gt;Lys) is a beta thalassemic hemoglobinopathy found predominantly in Southeast Asia. The mutant hemoglobin has an electrophoretic mobility similar to Hb C under alkaline conditions, but can be resolved by acid electrophoresis or isoelectric focusing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/73\">",
"     73",
"    </a>",
"    ]. The mutation in codon 26 activates a cryptic splice site within the first intron of the beta E gene, causing alternate splicing and decreased expression of the structural mutant [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/74\">",
"     74",
"    </a>",
"    ]. As a result, Hb E comprises only 30 percent of the total hemoglobin in patients with compound heterozygosity for the sickle cell and Hb E genes.",
"   </p>",
"   <p>",
"    Heterozygotes and homozygotes for Hb E are asymptomatic with minimal anemia and microcytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/75\">",
"     75",
"    </a>",
"    ]. Hb SE disease may cause only mild hemolysis, no vasoocclusive complications, and no remarkable abnormality of red blood cell morphology in those 18 years of age or less [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/76\">",
"     76",
"    </a>",
"    ]. However, there are several case reports of more severe manifestations, such as hematuria and a probable splenic infarct during air travel [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/77\">",
"     77",
"    </a>",
"    ] and acute chest syndrome and reversible bone marrow necrosis associated with parvovirus B19 infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/78\">",
"     78",
"    </a>",
"    ]. In one family, three siblings had moderately severe hemolysis, jaundice, bone pain, splenic infarction, recurrent pneumonia, and irreversibly sickled cells on the peripheral blood smear [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/79\">",
"     79",
"    </a>",
"    ]. It has been suggested that patients with Hb SE disease be followed and managed in a similar fashion as those with Hb",
"    <span class=\"nowrap\">",
"     S/beta",
"     <sup>",
"      +",
"     </sup>",
"    </span>",
"    thalassemia, and treated appropriately when they develop sickling-related symptoms and complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H316192\">",
"    <span class=\"h1\">",
"     SICKLE CELL DISEASE IN HETEROZYGOTES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of sickle variant hemoglobins that, in the heterozygote, produce clinical sickle cell disease. This occurs when there are two mutations in the same beta globin chain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13960?source=see_link&amp;anchor=H7649235#H7649235\">",
"     \"Sickle cell trait\", section on 'Symptoms of sickle cell disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two most common types of variants are Hemoglobin S-Antilles and Hemoglobin S-Oman. Heterozygotes for Hemoglobin S-Antilles have a mild hemolytic anemia with sickle cells on their blood film. These patients may also develop painful episodes and other symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5209/abstract/80\">",
"     80",
"    </a>",
"    ]. On hemoglobin electrophoresis, these conditions may appear as sickle trait. Additional molecular and DNA techniques are required to make these diagnoses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22112655\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of sickle cell syndromes that result from inheritance of the sickle cell gene in compound heterozygosity with other mutant beta globin genes. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hemoglobin SC disease (HbSC",
"      </strong>",
"      ) &mdash; Individuals with HbSC disease are at risk for the same complications as those with HbSS disease, but at a decreased frequency. Anemia is mild and splenomegaly may be the only finding on physical examination. The blood smear shows target cells, folded cells, occasional irreversibly sickled cells and occasional cells containing hemoglobin crystals. HbS and HbC are seen in equal amounts on electrophoresis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hb SC disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Sickle beta",
"      </strong>",
"      <strong>",
"       <sup>",
"        +",
"       </sup>",
"      </strong>",
"      <strong>",
"       thalassemia",
"      </strong>",
"      &mdash; Individuals with sickle-beta",
"      <sup>",
"       +",
"      </sup>",
"      thalassemia have an illness that is less severe than HbSS disease. Disease severity is inversely related to the amount of HbA present, which varies from 5 to 30 percent. The peripheral smear shows the presence of hypochromic, microcytic red cells and levels of HbA2 are increased. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Sickle-beta thalassemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Sickle beta",
"      </strong>",
"      <strong>",
"       <sup>",
"        0",
"       </sup>",
"      </strong>",
"      <strong>",
"       thalassemia",
"      </strong>",
"      &mdash; Patients with sickle beta",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia have severe disease which may be somewhat less severe than HbSS disease. This variant is more common in the Greek and Mediterranean regions than in the African-American population. No HbA is present on electrophoresis. It is distinguished from HbSS disease by the presence of hypochromic, microcytic red cells and increased levels of HbA2. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Sickle-beta thalassemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Sickle alpha thalassemia",
"      </strong>",
"      &mdash; The clinical manifestations and degree of anemia in sickle alpha thalassemia are generally less severe than those seen in sickle beta",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia. HbA2 levels are increased according to the number of alpha globin gene deletions. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Sickle-alpha thalassemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Sickle hereditary persistence of HbF (sickle HPFH)",
"      </strong>",
"      &mdash; Subjects with pancellular sickle HPFH are not anemic, do not suffer from vasoocclusive episodes, and may have HbF levels as high as 35 percent. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Sickle-hereditary persistence of fetal Hb'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Other variants",
"      </strong>",
"      &mdash; Other sickle cell syndrome variants (eg, delta beta",
"      <sup>",
"       0",
"      </sup>",
"      thalassemia, Hb Lepore, HbD, HbO Arab, HbE) are less common and are discussed in the text above.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/1\">",
"      Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997; 337:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/2\">",
"      Kaul DK, Fabry ME, Costantini F, et al. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse. J Clin Invest 1995; 96:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/3\">",
"      Motulsky AG. Frequency of sickling disorders in U.S. blacks. N Engl J Med 1973; 288:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/4\">",
"      Bunn HF, Noguchi CT, Hofrichter J, et al. Molecular and cellular pathogenesis of hemoglobin SC disease. Proc Natl Acad Sci U S A 1982; 79:7527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/5\">",
"      Hirsch RE, Raventos-Suarez C, Olson JA, Nagel RL. Ligand state of intraerythrocytic circulating HbC crystals in homozygote CC patients. Blood 1985; 66:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/6\">",
"      Fabry ME, Kaul DK, Raventos-Suarez C, et al. SC erythrocytes have an abnormally high intracellular hemoglobin concentration. Pathophysiological consequences. J Clin Invest 1982; 70:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/7\">",
"      Ballas SK, Lewis CN, Noone AM, et al. Clinical, hematological, and biochemical features of Hb SC disease. Am J Hematol 1982; 13:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/8\">",
"      RIVER GL, ROBBINS AB, SCHWARTZ SO. S-C hemoglobin: a clinical study. Blood 1961; 18:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/9\">",
"      West MS, Wethers D, Smith J, Steinberg M. Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. J Clin Epidemiol 1992; 45:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/10\">",
"      McCurdy PR. 32-DFP and 51-Cr for measurement of red cell life span in abnormal hemoglobin syndromes. Blood 1969; 33:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/11\">",
"      Lawrence C, Fabry ME, Nagel RL. The unique red cell heterogeneity of SC disease: crystal formation, dense reticulocytes, and unusual morphology. Blood 1991; 78:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/12\">",
"      Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/13\">",
"      Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol 1996; 17:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/14\">",
"      Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/15\">",
"      Powars DR, Elliott-Mills DD, Chan L, et al. Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Ann Intern Med 1991; 115:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/16\">",
"      Zarkowsky HS, Gallagher D, Gill FM, et al. Bacteremia in sickle hemoglobinopathies. J Pediatr 1986; 109:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/17\">",
"      Buchanan GR, Smith SJ, Holtkamp CA, Fuseler JP. Bacterial infection and splenic reticuloendothelial function in children with hemoglobin SC disease. Pediatrics 1983; 72:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/18\">",
"      Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. Blood 1989; 74:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/19\">",
"      Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991; 325:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/20\">",
"      Platt OS, Rosenstock W, Espeland MA. Influence of sickle hemoglobinopathies on growth and development. N Engl J Med 1984; 311:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/21\">",
"      Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/22\">",
"      Condon PI, Hayes RJ, Serjeant GR. Retinal and choroidal neovascularization in sickle cell disease. Trans Ophthalmol Soc U K 1980; 100:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/23\">",
"      Lane PA, O'Connell JL, Lear JL, et al. Functional asplenia in hemoglobin SC disease. Blood 1995; 85:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/24\">",
"      Orringer EP, Fowler VG Jr, Owens CM, et al. Case report: splenic infarction and acute splenic sequestration in adults with hemoglobin SC disease. Am J Med Sci 1991; 302:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/25\">",
"      Michlitsch J, Azimi M, Hoppe C, et al. Newborn screening for hemoglobinopathies in California. Pediatr Blood Cancer 2009; 52:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/26\">",
"      SINGER K, SINGER L, GOLDBERG SR. Studies on abnormal hemoglobins. XI. Sickle cell-thalassemia disease in the Negro; the significance of the S+A+F and S+A patterns obtained by hemoglobin analysis. Blood 1955; 10:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/27\">",
"      SMITH EW, CONLEY CL. Clinical features of the genetic variants of sickle cell disease. Bull Johns Hopkins Hosp 1954; 94:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/28\">",
"      Gonzalez-Redondo JM, Stoming TA, Lanclos KD, et al. Clinical and genetic heterogeneity in black patients with homozygous beta-thalassemia from the southeastern United States. Blood 1988; 72:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/29\">",
"      Gonzalez-Redondo JM, Kutlar A, Kutlar F, et al. Molecular characterization of Hb S(C) beta-thalassemia in American blacks. Am J Hematol 1991; 38:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/30\">",
"      Christakis J, Vavatsi N, Hassapopoulou H, et al. A comparison of sickle cell syndromes in northern Greece. Br J Haematol 1991; 77:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/31\">",
"      Serjeant GR, Sommereux AM, Stevenson M, et al. Comparison of sickle cell-beta0 thalassaemia with homozygous sickle cell disease. Br J Haematol 1979; 41:83.",
"     </a>",
"    </li>",
"    <li>",
"     Serjeant GR, Serjeant BE. Comparison of sickle cell-b&ordm; thalassemia and sickle cell-b+ thalassemia in Black populations. In: Thalassemia: Advances in detection and treatment, Birth Defects Original Article Series, Cao A, Carcassi U, Rowley PT (Eds), Alan R Liss, New York 1982. p.233.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/33\">",
"      Zafeiriou DI, Prengler M, Gombakis N, et al. Central nervous system abnormalities in asymptomatic young patients with Sbeta-thalassemia. Ann Neurol 2004; 55:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/34\">",
"      Martin CR, Johnson CS, Cobb C, et al. Myocardial infarction in sickle cell disease. J Natl Med Assoc 1996; 88:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/35\">",
"      James TN, Riddick L, Massing GK. Sickle cells and sudden death: morphologic abnormalities of the cardiac conduction system. J Lab Clin Med 1994; 124:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/36\">",
"      Acar P, Maunoury C, de Montalembert M, Dulac Y. [Abnormalities of myocardial perfusion in sickle cell disease in childhood: a study of myocardial scintigraphy]. Arch Mal Coeur Vaiss 2003; 96:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/37\">",
"      Aessopos A, Tsironi M, Vassiliadis I, et al. Exercise-induced myocardial perfusion abnormalities in sickle beta-thalassemia: Tc-99m tetrofosmin gated SPECT imaging study. Am J Med 2001; 111:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/38\">",
"      Bunn HF. Subunit assembly of hemoglobin: an important determinant of hematologic phenotype. Blood 1987; 69:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/39\">",
"      Embury SH, Lebo RV, Dozy AM, Kan YW. Organization of the alpha-globin genes in the Chinese alpha-thalassemia syndromes. J Clin Invest 1979; 63:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/40\">",
"      Embury SH, Miller JA, Dozy AM, et al. Two different molecular organizations account for the single alpha-globin gene of the alpha-thalassemia-2 genotype. J Clin Invest 1980; 66:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/41\">",
"      Dozy AM, Kan YW, Embury SH, et al. alpha-Globin gene organisation in blacks precludes the severe form of alpha-thalassaemia. Nature 1979; 280:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/42\">",
"      Embury SH, Dozy AM, Miller J, et al. Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia. N Engl J Med 1982; 306:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/43\">",
"      Higgs DR, Aldridge BE, Lamb J, et al. The interaction of alpha-thalassemia and homozygous sickle-cell disease. N Engl J Med 1982; 306:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/44\">",
"      Steinberg MH, Rosenstock W, Coleman MB, et al. Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia. Blood 1984; 63:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/45\">",
"      de Ceulaer K, Higgs DR, Weatherall DJ, et al. alpha-Thalassemia reduces the hemolytic rate in homozygous sickle-cell disease. N Engl J Med 1983; 309:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/46\">",
"      Stevens MC, Maude GH, Beckford M, et al. Alpha thalassemia and the hematology of homozygous sickle cell disease in childhood. Blood 1986; 67:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/47\">",
"      Embury SH, Clark MR, Monroy G, Mohandas N. Concurrent sickle cell anemia and alpha-thalassemia. Effect on pathological properties of sickle erythrocytes. J Clin Invest 1984; 73:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/48\">",
"      Dover GJ, Chang VT, Boyer SH, et al. The cellular basis for different fetal hemoglobin levels among sickle cell individuals with two, three, and four alpha-globin genes. Blood 1987; 69:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/49\">",
"      Thomas PW, Higgs DR, Serjeant GR. Benign clinical course in homozygous sickle cell disease: a search for predictors. J Clin Epidemiol 1997; 50:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/50\">",
"      K&eacute;clard L, Romana M, Lavocat E, et al. Sickle cell disorder, beta-globin gene cluster haplotypes and alpha-thalassemia in neonates and adults from Guadeloupe. Am J Hematol 1997; 55:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/51\">",
"      Milner PF, Kraus AP, Sebes JI, et al. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop Relat Res 1993; :136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/52\">",
"      Fox PD, Dunn DT, Morris JS, Serjeant GR. Risk factors for proliferative sickle retinopathy. Br J Ophthalmol 1990; 74:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/53\">",
"      Marcus SJ, Kinney TR, Schultz WH, et al. Quantitative analysis of erythrocytes containing fetal hemoglobin (F cells) in children with sickle cell disease. Am J Hematol 1997; 54:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/54\">",
"      Forget BG. Molecular basis of hereditary persistence of fetal hemoglobin. Ann N Y Acad Sci 1998; 850:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/55\">",
"      Craig JE, Rochette J, Sampietro M, et al. Genetic heterogeneity in heterocellular hereditary persistence of fetal hemoglobin. Blood 1997; 90:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/56\">",
"      Craig JE, Rochette J, Fisher CA, et al. Dissecting the loci controlling fetal haemoglobin production on chromosomes 11p and 6q by the regressive approach. Nat Genet 1996; 12:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/57\">",
"      Bradley TB, Brawner JN, Conley CL. Further observations on an inherited anomaly characterized by persisetnce of fetal hemoglobin. Bull Johns Hopk Hosp 1961; 108:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/58\">",
"      CONLEY CL, WEATHERALL DJ, RICHARDSON SN, et al. Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore. Blood 1963; 21:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/59\">",
"      Murray N, Serjeant BE, Serjeant GR. Sickle cell-hereditary persistence of fetal haemoglobin and its differentiation from other sickle cell syndromes. Br J Haematol 1988; 69:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/60\">",
"      Kinney TR, Friedman S, Cifuentes E, et al. Variations in globin synthesis in delta-beta-thalassaemia. Br J Haematol 1978; 38:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/61\">",
"      O'Reilly RA. A kindred with hemoglobin Lepore. JAMA 1976; 236:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/62\">",
"      Seward DP, Ware RE, Kinney TR. Hemoglobin sickle-Lepore: report of two siblings and review of the literature. Am J Hematol 1993; 44:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/63\">",
"      Stevens MC, Lehmann H, Mason KP, et al. Sickle cell-Hb Lepore Boston syndrome. Uncommon differential diagnosis to homozygous sickle cell disease. Am J Dis Child 1982; 136:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/64\">",
"      Schnee J, Aulehla-Scholz C, Eigel A, Horst J. Hb D Los Angeles (D-Punjab) and Hb Presbyterian: analysis of the defect at the DNA level. Hum Genet 1990; 84:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/65\">",
"      STURGEON P, ITANO HA, BERGREN WR. Clinical manifestations of inherited abnormal hemoglobins. I. The interaction of hemoglobin-S with hemoglobin-D. Blood 1955; 10:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/66\">",
"      Adachi K, Kim J, Ballas S, et al. Facilitation of Hb S polymerization by the substitution of Glu for Gln at beta 121. J Biol Chem 1988; 263:5607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/67\">",
"      Cooke JV, Mack JK. Sickle-cell anemia in a white American family. J Pediatr 1934; 5:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/68\">",
"      Kelleher JF Jr, Park JO, Kim HC, Schroeder WA. Life-threatening complications in a child with hemoglobin SD-Los Angeles disease. Hemoglobin 1984; 8:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/69\">",
"      Schmugge M, Frischknecht H, Yonekawa Y, et al. Stroke in hemoglobin (SD) sickle cell disease with moyamoya: successful hydroxyurea treatment after cerebrovascular bypass surgery. Blood 2001; 97:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/70\">",
"      Ramot B, Fisher S, Remez D, et al. Haemoglobin O in An Arab Family. Br Med J 1960; 2:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/71\">",
"      Milner PF, Miller C, Grey R, et al. Hemoglobin O arab in four negro families and its interaction with hemoglobin S and hemoglobin C. N Engl J Med 1970; 283:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/72\">",
"      Zimmerman SA, O'Branski EE, Rosse WF, Ware RE. Hemoglobin S/O(Arab): thirteen new cases and review of the literature. Am J Hematol 1999; 60:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/73\">",
"      CHERNOFF AI, MINNICH V, CHONGCHAREONSUK S. Hemoglobin E, a hereditary abnormality of human hemoglobin. Science 1954; 120:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/74\">",
"      Orkin SH, Kazazian HH Jr, Antonarakis SE, et al. Abnormal RNA processing due to the exon mutation of beta E-globin gene. Nature 1982; 300:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/75\">",
"      Rees DC, Styles L, Vichinsky EP, et al. The hemoglobin E syndromes. Ann N Y Acad Sci 1998; 850:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/76\">",
"      Masiello D, Heeney MM, Adewoye AH, et al. Hemoglobin SE disease: a concise review. Am J Hematol 2007; 82:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/77\">",
"      Schroeder WA, Powars D, Reynolds RD, Fisher JI. Hb-E in combination with Hb-S and Hb-C in a black family. Hemoglobin 1977; 1:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/78\">",
"      Eichhorn RF, Buurke EJ, Blok P, et al. Sickle cell-like crisis and bone marrow necrosis associated with parvovirus B19 infection and heterozygosity for haemoglobins S and E. J Intern Med 1999; 245:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/79\">",
"      Rosenberg MR. In vivo and in vitro interactions of human haemoglobins A,S and C with a variant haemoglobin E. Nature 1968; 219:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5209/abstract/80\">",
"      Monplaisir N, Merault G, Poyart C, et al. Hemoglobin S Antilles: a variant with lower solubility than hemoglobin S and producing sickle cell disease in heterozygotes. Proc Natl Acad Sci U S A 1986; 83:9363.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7115 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-24A2ECD58B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5209=[""].join("\n");
var outline_f5_5_5209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22112655\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HB SC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SICKLE-BETA THALASSEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SICKLE-ALPHA THALASSEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SICKLE-HEREDITARY PERSISTENCE OF FETAL HB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SICKLE-DELTA BETA(0) THALASSEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SICKLE-HB LEPORE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SICKLE-HB D DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SICKLE-HB O ARAB DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SICKLE-HB E DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H316192\">",
"      SICKLE CELL DISEASE IN HETEROZYGOTES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22112655\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7115\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7115|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/51/9023\" title=\"diagnostic image 1\">",
"      Hemoglobin electrophoresis at alkaline pH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7115|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/31/41469\" title=\"figure 1\">",
"      CVA in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7115|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/19/43318\" title=\"picture 1\">",
"      Hemoglobin SC disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7115|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/56/18316\" title=\"table 1\">",
"      Hgb electrophoresis patterns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=related_link\">",
"      Clinical variability in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42856?source=related_link\">",
"      Diagnosis of sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9129?source=related_link\">",
"      Molecular pathology of the thalassemic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36025?source=related_link\">",
"      Pathophysiology of alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=related_link\">",
"      Pathophysiology of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13960?source=related_link\">",
"      Sickle cell trait",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=related_link\">",
"      Sickle hemoglobin polymer: Structure and functional properties",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_5_5210="Overview of the causes of chronic diarrhea in children";
var content_f5_5_5210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the causes of chronic diarrhea in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/5/5210/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/5/5210/contributors\">",
"     Richard Kellermayer, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/5/5210/contributors\">",
"     Robert J Shulman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/5/5210/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/5/5210/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/5/5210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/5/5210/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/5/5210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major causes and the prevalence of chronic diarrhea differ between developed and developing countries. In the developing world, chronic diarrhea is typically associated with serial enteric infections and malnutrition; it is manifested by a chronic enteropathy, with impaired mucosal healing and diminished digestive and absorptive capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In developed countries, children are less likely to be exposed to serial enteric infections and malnutrition. In these populations, chronic diarrhea is more likely to be induced by underlying disease causing malabsorption or maldigestion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. However, enteric infections (particularly in immunocompromised patients), malnutrition, and dietary factors (eg, excessive consumption of juice), play a role in some cases.",
"   </p>",
"   <p>",
"    The difference in pathophysiology underlying most cases of chronic diarrhea in developing countries as compared to those in developed countries calls for different approaches to diagnosis and management in the two settings. The diagnosis and treatment of chronic diarrhea in developing countries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43609?source=see_link\">",
"     \"Persistent diarrhea in children in developing countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathophysiology and management of diarrheal diseases in developed countries will be reviewed here. The approach to diagnosing the cause of these diarrheal diseases is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35511?source=see_link\">",
"     \"Approach to the diagnosis of chronic diarrhea in children in developed countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic diarrhea is defined as stool volume of more than 10",
"    <span class=\"nowrap\">",
"     grams/kg/day",
"    </span>",
"    in infants and toddlers, or more than 200",
"    <span class=\"nowrap\">",
"     grams/day",
"    </span>",
"    in older children for more than 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/6\">",
"     6",
"    </a>",
"    ]. This typically translates to persistent loose or watery stools occurring at least three times a day, where the change in stool consistency is more important than stool frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/7\">",
"     7",
"    </a>",
"    ]. Some authors make a distinction between chronic diarrhea, which they define as having a gradual onset, from persistent diarrhea, which they define as having a sudden onset. However, it is frequently difficult to identify the time of onset of the diarrhea and delineation of the two entities can be problematic. Consequently, for the purposes of this review we will not differentiate between persistent and chronic diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE AND MORBIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic diarrhea is a common condition. According to one review, diarrhea lasting more than two to four weeks occurs in up to 3 to 5 percent of the population worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/8\">",
"     8",
"    </a>",
"    ]. It is generally more frequent in males, with a male-to-female ratio of 1.2 to 2.6:1 in the age range of 6 to 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the developed world, the prevalence of chronic diarrhea is substantially lower. In the United States, there is approximately one case of persistent diarrhea per five person-years in infants and young children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/12\">",
"     12",
"    </a>",
"    ]. Most of these cases are self-limited, with fewer than 28 percent presenting for medical care. Fewer than 100 per 10,000 children are hospitalized in the United States for diarrheal disease, and this figure includes many cases of acute diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic pathophysiology of all diarrheas is incomplete absorption of water from the intestinal lumen either because of a reduced rate of net water absorption (related to impaired electrolyte absorption or excessive electrolyte secretion) or because of osmotic retention of water in the lumen. Reduction of net water absorption by as little as one percent may be sufficient to cause diarrhea. Consequently, even relatively modest compromise of absorptive function can lead to loose stools [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/14\">",
"     14",
"    </a>",
"    ], and many conditions can be associated with diarrhea, the frequencies and characteristics of which vary depending on age and socioeconomic status (",
"    <a class=\"graphic graphic_table graphicRef56837 \" href=\"UTD.htm?25/32/26125\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In developed countries, noninfectious causes of diarrhea share a higher proportion in the etiology of chronic diarrhea. Consequently, a wide variety of etiologies should be considered, including functional and infectious causes but also heritable disorders of immune regulation, macronutrient digestion, mucosal barrier function, and transport [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     FUNCTIONAL DIARRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional diarrhea is defined as the painless passage of three or more large, unformed stools during waking hours for four or more weeks, with onset in infancy or the preschool years, and without failure to thrive or a specific definable cause [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/15\">",
"     15",
"    </a>",
"    ]. This common, benign disorder has also been termed chronic nonspecific diarrhea of childhood or toddler's diarrhea.",
"   </p>",
"   <p>",
"    Children with functional diarrhea usually pass stools only during waking hours. Early morning stools typically are large and semi-formed, then stools become progressively looser as the day progresses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/16\">",
"     16",
"    </a>",
"    ]. Virtually all children develop normal bowel patterns by four years of age. In some cases, the diarrhea is associated with excessive intake of fruit juice,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    , or other osmotically active carbohydrates, and will improve when the intake of these foods is moderated. Other than this precaution, restrictions to the diet or other interventions are not necessary or helpful. In particular, restriction of dietary fat may be counter-productive [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the evaluation suggests functional diarrhea, we suggest trials of the following dietary changes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduce or eliminate fruit juice or other osmotically active carbohydrates. Apple, prune, and pear juice contain",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"       sorbitol",
"      </a>",
"      and have a particularly high osmotic load.",
"     </li>",
"     <li>",
"      Liberalize the fat content of the diet to 35 to 50 percent of total calories.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other than these two measures, alterations in diet are not helpful and are sometimes counter-productive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INFECTIOUS CAUSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Postenteritis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most enteric infections in otherwise healthy children resolve within 14 days and do not develop into a chronic diarrhea illness. However, in a minority of patients, an acute gastroenteritis can trigger persistent diarrhea by causing mucosal damage to the small intestine, termed a \"postenteritis syndrome\" [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/7,12,18,19\">",
"     7,12,18,19",
"    </a>",
"    ]. The mechanisms underlying this syndrome are not fully understood. Contrary to previous hypotheses, sensitization to food antigens and secondary disaccharidase deficiency, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/62/14306?source=see_link\">",
"     lactase",
"    </a>",
"    deficiency (causing lactose intolerance), are uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/7,20\">",
"     7,20",
"    </a>",
"    ]. Therefore, international guidelines discourage the use of hypoallergenic or diluted milk formulas during acute gastroenteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Recurrent or sequential enteric infections may be responsible for some of these cases.",
"   </p>",
"   <p>",
"    In some cases, treatment with probiotic bacteria may facilitate recovery from postenteritis syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In immunocompromised patients, common infectious causes of acute diarrhea, such as Campylobacter or Salmonella, can cause persistent diarrhea. Chronic infections with these pathogens are uncommon in immunocompetent hosts. Bacterial cultures should be part of the initial diagnostic evaluation for all patients if the stool contains blood, or for immunocompromised patients regardless of fecal blood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29513?source=see_link\">",
"     \"Diagnostic approach to lower gastrointestinal bleeding in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Intestinal complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children recently treated with antibiotics, Clostridium difficile may cause a colitis characterized by \"pseudomembrane\" formation. The enzyme immunoassay available in most laboratories detects C. difficile toxins A and B with high specificity but only moderate sensitivity. Polymerase chain reaction (PCR) based diagnostic methods can enhance the detection rate [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link\">",
"     \"Clostridium difficile infection in children: Clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=see_link\">",
"     \"Clostridium difficile infection in children: Approach to diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enterotoxigenic strains of Staphylococcus aureus typically cause acute gastrointestinal symptoms in children or adults, due to the effects of ingested pre-formed toxin produced in contaminated food. However, in two case reports, enteric infections with these strains were associated with chronic diarrhea and an enteropathy in neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/27\">",
"     27",
"    </a>",
"    ]. This raises the possibility that these strains might cause disease by chronic colonization of the neonatal gut, but the reports do not establish causality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Parasites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal parasites are an uncommon cause of chronic diarrhea in developed countries, except among individuals with an immunodeficiency. Specific antigen assays for Giardia and examination from the stool for parasites is imperative for children with known immunodeficiencies or with a history of travel to endemic areas. These tests are also an appropriate step in the evaluation of immunocompetent children if initial testing fails to determine a cause of the chronic diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a specific parasite is identified, treatment with specific medications is generally indicated, although the organism may not always be the cause of the diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/28\">",
"     28",
"    </a>",
"    ]. Empiric therapy for enteric pathogens is generally not advisable, except in cases with special characteristics in developing countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17335?source=see_link\">",
"     \"Antiprotozoal therapies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23221?source=see_link\">",
"     \"Anthelminthic therapies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43609?source=see_link\">",
"     \"Persistent diarrhea in children in developing countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Syndromic persistent diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally children in developed countries will develop a pattern in which enteric infection triggers a cycle of undernutrition, immune compromise and reinfection, resembling the syndromic persistent diarrhea that is more commonly seen in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. This pattern is uncommon in developed countries except in children with an underlying immunodeficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43609?source=see_link\">",
"     \"Persistent diarrhea in children in developing countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     IMMUNE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic diarrhea may present as a complication of a known immune deficiency such as HIV disease. In this case, the evaluation should focus on potential infectious causes of the diarrhea, particularly parasites and opportunistic infections such as Cryptosporidium, Isospora, and Cyclospora [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/7,34\">",
"     7,34",
"    </a>",
"    ]. These children also are at risk for persistent infectious pathogens that typically cause acute diarrheas, such as rotavirus [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38551?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with diarrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=see_link&amp;anchor=H18840561#H18840561\">",
"     \"Natural history and classification of pediatric HIV infection\", section on 'Other'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic diarrhea also may be a presenting symptom of immune deficiency in a child. When a patient is infected with an unusual pathogen, or has multiple or recurrent infections of the gastrointestinal tract or elsewhere, further evaluation for immune deficiency is required. In rare instances, live vaccines may call attention to the potential diagnosis of immunodeficiency by inducing chronic infection. As an example, vaccine-acquired chronic rotavirus diarrhea has been observed in infants with severe combined immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ABNORMAL IMMUNE RESPONSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease (also known as gluten-sensitive enteropathy or nontropical sprue) is an immune-mediated inflammation of the small intestine caused by sensitivity to dietary gluten and related proteins in genetically sensitive individuals. The disorder is common, occurring in 0.5 to 1 percent of the general population in most countries. Celiac disease often presents as chronic diarrhea, with or without malnutrition, during late infancy or early childhood.",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, and management of celiac disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7929?source=see_link\">",
"     \"Management of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcerative colitis and Crohn&rsquo;s disease are idiopathic chronic inflammatory diseases (IBD) of the bowel. These disorders typically present with gradual onset of chronic diarrhea, with or without blood, from mid-childhood through adulthood. Infantile and very early onset IBD (onset at age less than six years) appears to be a distinct subset of these diseases, in which clinical and genetic characteristics can be unique compared with later-onset cases of IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Allergic enteropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An abnormal immune response to food proteins can cause a",
"    <span class=\"nowrap\">",
"     proctitis/colitis",
"    </span>",
"    or an enteropathy. The former tends to present as bloody diarrhea and is frequently triggered by cow's milk protein in infants. The latter presents as non-bloody diarrhea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    as failure to thrive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Eosinophilic gastroenteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is an incompletely understood disorder that is sometimes but not always associated with an identifiable dietary antigen. Approximately one-half of patients have allergic disease, such as asthma, defined food sensitivities, eczema, or rhinitis; some patients have elevated serum IgE levels; rare patients have IgE antibodies directed against specific foods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3479327\">",
"    <span class=\"h2\">",
"     Microscopic and collagenous colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microscopic colitis typically presents with chronic watery nonbloody diarrhea. It typically occurs in middle-aged adults, but occasionally presents in children. The endoscopy is grossly normal, but histopathology reveals abnormal inflammatory findings, characterized by a collagenous colitis or lymphocytic colitis, sometimes with an eosinophilic infiltrate. In some cases, this disorder may represent an overlap with the eosinophilic gastroenteropathies. Microscopic colitis in children usually responds well to aminosalicylic acid (5-ASA) medications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/38\">",
"     38",
"    </a>",
"    ]. Some cases in adults have been successfully treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/48/35584?source=see_link\">",
"     budesonide",
"    </a>",
"    . Collagenous colitis is a related form of colitis that has been reported in a few children. The colon appears grossly normal, but biopsies show a thickened subepithelial collagenous band in the colonic mucosa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27530?source=see_link\">",
"     \"Lymphocytic and collagenous colitis (microscopic colitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Autoimmune enteropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune enteropathies are rare disorders that may present as severe diarrhea during infancy or toddlerhood. The diarrhea may be isolated, or may occur in association with diabetes mellitus as part of the IPEX syndrome (",
"    <strong>",
"     I",
"    </strong>",
"    mmune dysregulation,",
"    <strong>",
"     P",
"    </strong>",
"    olyendocrinopathy and",
"    <strong>",
"     E",
"    </strong>",
"    nteropathy,",
"    <strong>",
"     X",
"    </strong>",
"    -linked), which is associated with mutations in the FOXP3 gene. IPEX is characterized by chronic diarrhea, which usually begins in infancy, dermatitis, autoimmune endocrinopathy (diabetes mellitus, thyroiditis). Antienterocyte antibodies may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25850?source=see_link\">",
"     \"IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Autoimmune polyendocrine syndrome 1 (APS-1), also known as autoimmune polyendocrinopathy-candidiasis ectodermal dystrophy (APECED), is one of several autoimmune disorders caused by mutations in the autoimmune regulator gene (AIRE). Features include hypoparathyroidism and adrenal insufficiency, and about 25 percent of patients develop autoimmune enteritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Autoimmune adrenalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other genetically uncharacterized forms of autoimmune enteropathies also exist (",
"    <a class=\"graphic graphic_table graphicRef73777 \" href=\"UTD.htm?20/7/20606\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MALDIGESTION OF FAT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic fibrosis is the most common cause of pancreatic exocrine insufficiency in children. The disease may present at birth with meconium ileus, or may be suggested later by gastrointestinal symptoms of fat malabsorption, failure to thrive, rectal prolapse (particularly in the setting of diarrhea) or pulmonary symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other causes of pancreatic insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of pancreatic exocrine insufficiency include Shwachman-Diamond syndrome (associated with bone marrow failure and skeletal abnormalities), and two rare disorders, Pearson syndrome and Johanson-Blizzard syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33400?source=see_link\">",
"     \"Shwachman-Diamond syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27779023\">",
"    <span class=\"h1\">",
"     CHOLERHEIC DIARRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have undergone resection of the terminal ileum have impaired absorption of bile acids. If sufficient bile acids enter the colon, they may cause a secretory diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=see_link&amp;anchor=H2#H2\">",
"     \"Chronic complications of the short bowel syndrome in children\", section on 'Watery diarrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, patients who have had a cholecystectomy can develop cholerheic diarrhea because the continuous drainage of bile into the small bowel may overcome the terminal ileum&rsquo;s reabsorptive capacity. Management in adolescents is similar to that in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=see_link&amp;anchor=H16433027#H16433027\">",
"     \"Approach to the adult with chronic diarrhea in developed countries\", section on 'Cholecystectomy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL PROTEIN LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms of gastrointestinal protein loss include hypoalbuminemia and reduced concentrations of serum immune globulins. When severe, clinically evident edema is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=see_link\">",
"     \"Protein-losing gastroenteropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Mucosal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many diseases affecting the intestinal mucosa may cause excessive loss of protein through the gastrointestinal tract. Protein losses may be caused by inflammatory exudation through mucosal erosions (eg, inflammatory bowel disease), or to increased mucosal permeability without erosions (eg, celiac disease). In most such cases the protein losses will be accompanied by other signs and symptoms pointing to the cause of the diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Lymphatic obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstruction of the intestinal lymphatics impairs lymph flow and increases pressure in the intestinal lymphatics. This leads to leakage of lymph into the intestinal lumen, reduced recirculation of intestinal lymphocytes into the peripheral circulation, and decreased absorption of fat-soluble vitamins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=see_link\">",
"     \"Protein-losing gastroenteropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary intestinal lymphangiectasia is characterized by diffuse or localized ectasia of enteric lymphatics. The disease primarily affects children and young adults; the mean age of onset is approximately 11 years.",
"   </p>",
"   <p>",
"    Secondary intestinal lymphangiectasia may be caused by cardiac diseases, and chemotherapeutic, infectious, or toxic substances that are associated with inflammatory processes that cause retroperitoneal lymph node enlargement, portal hypertension or hepatic venous outflow obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     BOWEL OBSTRUCTION OR DYSMOTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial bowel obstruction or dysmotility may present with diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Hirschsprung's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disorder may present with dysmotility and diarrhea, and may progress to life-threatening toxic megacolon. Infants presenting with a history suggestive of Hirschsprung's disease should be evaluated promptly with abdominal plain films, followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    contrast studies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rectal suction biopsies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Intestinal pseudoobstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disorder of intestinal motility typically presents with constipation, but patients also may have periods of diarrhea, particularly if bacterial overgrowth supervenes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15354?source=see_link&amp;anchor=H15#H15\">",
"     \"Constipation in children: Etiology and diagnosis\", section on 'Other causes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=see_link\">",
"     \"Chronic intestinal pseudo-obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     CONGENITAL SECRETORY AND OSMOTIC DIARRHEAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital diarrhea can be caused by a variety of inherited disorders that disrupt nutrient digestion, absorption, or transport, enterocyte development and function, or enteroendocrine function. Specific genes have been identified for some of these disorders (",
"    <a class=\"graphic graphic_table graphicRef73777 \" href=\"UTD.htm?20/7/20606\">",
"     table 2",
"    </a>",
"    ). With the increasing use of whole-exome sequencing techniques, many more rare forms of congenital diarrhea are expected to be linked to genes contributing to appropriate intestinal fluid and electrolyte balance. One example for such discoveries is a mutation in diacylglycerol acyltransferase 1 (DGAT1), which catalyzes the final step in triglyceride synthesis; the mutation was detected in association with a familial form of congenital diarrhea in a family of Ashkenazi Jewish descent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a congenital diarrhea is suspected, stool electrolytes, pH, fat, and reducing substances should be measured. A trial of fasting should be performed to determine if the diarrhea is secretory or osmotic. A marked decrease in stool output during fasting and high stool osmolarity (eg, more than 40 mOsm greater than the serum osmolarity) suggests an osmotic diarrhea. In suspected cases of bile acid malabsorption, measurement of total and specific bile acids from stool or utilizing the gamma emitter slelenium-75-homocholic acid taurine (SeHCAT) may be considered, although these tests are usually not available on a clinical basis. Steatorrhea may also have osmotic mechanisms, but it tends to be lower volume and has a greasy rather than watery quality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35511?source=see_link&amp;anchor=H13#H13\">",
"     \"Approach to the diagnosis of chronic diarrhea in children in developed countries\", section on 'Selective testing according to stool type'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mucosal biopsies should be performed in patients with congenital diarrhea. The findings vary with etiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In congenital chloride diarrhea (CCD) and congenital sodium diarrhea (CSD), the histology is usually normal.",
"     </li>",
"     <li>",
"      In enteric anendocrinosis, the mucosal architecture is normal, but special stains demonstrate absence of enteroendocrine cells.",
"     </li>",
"     <li>",
"      In tufting enteropathy, the histopathology is characterized by villous atrophy, with disorganization of the surface enterocytes with focal crowding, resembling tufts [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In microvillus inclusion disease, light microscopy shows a variable degree of hypoplastic villus atrophy without crypt hyperplasia, and PAS-positive granules at the apical pole of enterocytes. Electron microscopy reveals characteristic microvillus inclusions and partial to total atrophy of microvilli on mature enterocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In chylomicron retention disease, light microscopy may reveal lipid droplets in duodenal enterocytes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whole-exome sequencing may be considered in select familial cases in which clinical, laboratory, and histologic investigations are non-revealing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Secretory diarrheas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital secretory diarrheas are rare and are characterized by profuse watery diarrhea beginning at birth. The diarrhea is so watery that it may be mistaken for urine in the diaper [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/42\">",
"     42",
"    </a>",
"    ]. Several of the causes of congenital secretory diarrhea are outlined below (",
"    <a class=\"graphic graphic_table graphicRef73777 \" href=\"UTD.htm?20/7/20606\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3479576\">",
"    <span class=\"h3\">",
"     Congenital chloride diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital chloride diarrhea (CCD,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/214700\">",
"     MIM #214700",
"    </a>",
"    ) is caused by a variety of mutations in the SLC26A3 (solute-linked carrier family 26 member A3) gene, which encodes for an epithelial anion exchanger [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. Most reported cases are in Finland, Poland, or Arab populations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/46\">",
"     46",
"    </a>",
"    ]. Because of excessive fecal losses of fluid and electrolytes, affected individuals present in the neonatal period with hyponatremia, hypochloremia, and metabolic alkalosis; there may be a history of polyhydramnios. The diagnosis of CCD is based on the finding of excessive fecal secretion of chloride, in which the chloride concentration exceeds the concentration of cations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. However, this finding is only reliable when the patient is in fluid and electrolyte balance. In the untreated patient, the volume and chloride content of the diarrhea may be artificially reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/46\">",
"     46",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Treatment consists of a high chloride intake to prevent volume depletion. Determining the optimal replacement dose is challenging because inadequate salt substitution paradoxically decreases diarrhea volume, and excessive salt administration also increases diarrhea volume by osmotic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/46\">",
"     46",
"    </a>",
"    ]. In some cases treatment with the proton pump inhibitor",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/23/24952?source=see_link\">",
"     omeprazole",
"    </a>",
"    appeared to reduce the stool volume and the fecal excretion of sodium and chloride by decreasing gastric chloride secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/49\">",
"     49",
"    </a>",
"    ]; in another report, butyrate appeared to be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. However, subsequent investigations suggest that the findings were artifacts of suboptimal salt substitution, and that these medications are not effective for treatment of CCD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3479583\">",
"    <span class=\"h3\">",
"     Congenital sodium diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital sodium diarrhea (CSD,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/270420\">",
"     MIM #270420",
"    </a>",
"    ) has a syndromic form which includes choanal or anal atresia and is associated with mutations in the SPINT2 gene, which are not seen in patients with isolated CSD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/53\">",
"     53",
"    </a>",
"    ]. The stool is alkaline and fecal sodium concentrations are high; metabolic acidosis and hyponatremia are typically present [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/42,48,54\">",
"     42,48,54",
"    </a>",
"    ]; there may be a history of polyhydramnios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3479590\">",
"    <span class=\"h3\">",
"     Microvillus inclusion disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microvillus inclusion disease (MID,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/251850\">",
"     MIM #251850",
"    </a>",
"    , also called microvillus atrophy) was associated with mutations in type Vb myosin motor protein (MYO5B) in several kindreds [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. The disorder typically presents with intractable secretory diarrhea shortly after birth, rapidly progressing to hypotonic dehydration and metabolic acidosis. A milder form of MID presents a few months later [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/52\">",
"     52",
"    </a>",
"    ]. Some patients have been successfully managed with parenteral nutrition including replacement of the large fecal losses of fluid and electrolytes, followed by intestinal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3479597\">",
"    <span class=\"h3\">",
"     Tufting enteropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tufting enteropathy (also known as intestinal epithelial cell dysplasia,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/613217\">",
"     MIM #613217",
"    </a>",
"    ) appears to be caused by mutations in the EpCAM (epithelial cell adhesion molecule) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The disorder presents with secretory diarrhea shortly after birth; the diarrhea volume is often less than in MID, and may partially respond to fasting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/60\">",
"     60",
"    </a>",
"    ]. Enteral feeding usually is unsuccessful; successful management with long-term parenteral nutrition",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intestinal transplantation has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/40,61\">",
"     40,61",
"    </a>",
"    ]. Chronic arthritis has also been reported in a case with a genetically supported diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/62\">",
"     62",
"    </a>",
"    ]. In a series of patients with the typical clinical presentation of congenital tufting enteropathy, many had associated ophthalmologic findings, including superficial punctate keratitis or conjunctival erosions; conjunctival biopsies revealed epithelial parakeratosis and tufts [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/63\">",
"     63",
"    </a>",
"    ]. Epithelial tufts also may be observed in congenital diarrheas associated with other gene defects, such as in the case of SPINT2-related disease. (See",
"    <a class=\"local\" href=\"#H3479583\">",
"     'Congenital sodium diarrhea'",
"    </a>",
"    above.). In such cases, genetic testing can be particularly helpful to define the diagnosis, prognosis, and potential therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3479604\">",
"    <span class=\"h3\">",
"     Enteric anendocrinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enteric anendocrinosis (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/610370\">",
"     MIM #610370",
"    </a>",
"    , also known as congenital malabsorptive diarrhea 4) is caused by mutations in neurogenin-3 (NEUROG3) and is associated with a paucity of enteroendocrine cells in the pancreas and intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/65\">",
"     65",
"    </a>",
"    ]. It is characterized by an osmotic diarrhea and later development of insulin-deficient diabetes, without anti-islet cell antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/52\">",
"     52",
"    </a>",
"    ]. Enteroendocrine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    enterochromaffin cell paucity can be caused by a variety of other mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Congenital bile acid malabsorption, also designated as primary bile acid diarrhea (PBAD,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim?term=613291\">",
"     MIM #613291",
"    </a>",
"    ), also known as type 2 idiopathic bile acid malabsorption (IBAM), has been linked to genetic defects in the ileal sodium-dependent bile acid transporter or solute carrier family 10",
"    <span class=\"nowrap\">",
"     (sodium/bile",
"    </span>",
"    acid cotransporter family), member 2 (",
"    <em>",
"     SLC10A2",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/67\">",
"     67",
"    </a>",
"    ]. However, only subsets of patients harbor defects or polymorphisms in this gene suggesting that there is genetic heterogeneity in this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Osmotic diarrheas",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast with the secretory diarrheas described above, congenital osmotic diarrheas cease during fasting or upon exclusion of certain dietary components that are maldigested by the patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucose-galactose malabsorption &mdash; Glucose-galactose malabsorption (",
"      <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/606824\">",
"       MIM #606824",
"      </a>",
"      ) presents with severe life-threatening diarrhea and dehydration during the neonatal period, caused by deficiency in the intestinal",
"      <span class=\"nowrap\">",
"       sodium/glucose",
"      </span>",
"      transporter [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/48,69\">",
"       48,69",
"      </a>",
"      ]. Patients are symptomatic as long as their diet includes lactose or its hydrolysis products, glucose and galactose. The diagnosis is suspected if the diarrhea resolves promptly when these sugars are eliminated, and confirmed by a positive glucose breath hydrogen test and normal intestinal biopsy. Treatment is with a fructose-based formula, and lifelong dietary restriction of the causative sugars.",
"     </li>",
"     <li>",
"      Congenital sucrase-isomaltase deficiency &mdash; Congenital sucrase-isomaltase deficiency (",
"      <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/222900\">",
"       MIM #222900",
"      </a>",
"      ) is rare in most populations, except among individuals of Eskimo or Canadian Native descent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/70\">",
"       70",
"      </a>",
"      ]. Infants are asymptomatic if their diet contains only lactose (eg, exclusively breast-fed infants), but typically develop chronic diarrhea after sucrose-containing formulas or foods are introduced. A number of mutations in the gene encoding sucrase-isomaltase have been described in affected individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/71,72\">",
"       71,72",
"      </a>",
"      ]. Case reports describe effective treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/12/16579?source=see_link\">",
"       sacrosidase",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/71,73\">",
"       71,73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Steatorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects in pancreatic enzyme activity and lipid trafficking tend to present with chronic low-volume diarrhea and failure to thrive during infancy, caused by fat malabsorption. These include abetalipoproteinemia (",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/200100\">",
"     MIM #200100",
"    </a>",
"    ) and defects of bile acid absorption (eg, primary bile acid malabsorption,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/613291\">",
"     MIM #613291",
"    </a>",
"    ), or of pancreatic enzyme production (eg, pancreatic lipase deficiency,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/246600\">",
"     MIM 246600",
"    </a>",
"    ). Neurologic symptoms may ensue, particularly in abetalipoproteinemia (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H10#H10\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Abetalipoproteinemia'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Chylomicron retention disease (also known as Anderson disease,",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/246700\">",
"     MIM #246700",
"    </a>",
"    ) is characterized by failure to secrete chylomicrons across the basolateral membrane of the enterocyte. Patients generally present with fat malabsorption, steatorrhea, and failure to thrive during infancy. The lipid distension of the enterocytes causes secondary malabsorption of carbohydrates and amino acids, which may improve with a low-fat diet [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     NEUROENDOCRINE TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroendocrine tumors affecting the gastrointestinal tract are rare in children, and tend to cause a secretory diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Gastrinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this syndrome, also known as Zollinger-Ellison syndrome, unregulated secretion of gastrin causes hypersecretion of gastric acid, with consequent peptic ulcer disease and chronic diarrhea. Fewer than 5 percent of patients present during adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/75\">",
"     75",
"    </a>",
"    ]. The disorder may be suspected in a patient presenting with unexplained peptic ulcer disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with a secretory diarrhea and fat malabsorption. Fasting serum gastrin levels are elevated 5 to 10 fold. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     VIPoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unregulated hypersecretion of vasoactive intestinal polypeptide (VIP) causes watery diarrhea, hypokalemia, and achlorhydria. VIPomas are very rare in children, but may occur as ganglioneuromas and ganglioneuroblastomas in the sympathetic ganglia and in the adrenal glands (rather than in the pancreas where they are often found in adults). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link\">",
"     \"The VIPoma syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, this disorder usually takes the form of cutaneous mastocytosis, consisting only of the skin lesions of urticaria pigmentosa, and is often self-limited [",
"    <a class=\"abstract\" href=\"UTD.htm?5/5/5210/abstract/76\">",
"     76",
"    </a>",
"    ]. A few children, particularly those presenting after 2 years of age, have systemic mastocytosis, which may include histamine-induced gastric hypersecretion and chronic diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     FACTITIOUS DIARRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factitious diarrhea may be characterized by a true increase in stool volume, which is self-induced (eg, laxative abuse), or the creation of an apparent increase in stool volume by the addition of various substances to the stool (eg, water or urine). Diagnosing factitious diarrhea is often difficult and requires alertness to this possibility, exclusion of other diseases, and may be aided by specific testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6246?source=see_link\">",
"     \"Factitious diarrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35511?source=see_link&amp;anchor=H4#H4\">",
"     \"Approach to the diagnosis of chronic diarrhea in children in developed countries\", section on 'Laboratory evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A practical definition of chronic diarrhea is the passage of loose or watery stools at least three times a day for more than two weeks. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causes of chronic diarrhea in children are diverse, including functional and infectious causes and also heritable disorders of immune regulation, macronutrient digestion, mucosal barrier function, and transport (",
"      <a class=\"graphic graphic_table graphicRef56837 \" href=\"UTD.htm?25/32/26125\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In developed countries, functional diarrhea accounts for a high proportion of chronic diarrheas in children. This tends to occur in otherwise healthy children, with onset in late infancy or the preschool years, and is self-limited. Appropriate interventions for such patients are to reduce or eliminate fruit juice or other osmotically active carbohydrates, and to liberalize the fat content of the diet. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Functional diarrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Celiac disease is also a relatively common cause of chronic diarrhea and can present with a wide range of symptom severity. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Celiac disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"       \"Clinical manifestations and diagnosis of celiac disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In developing countries, chronic diarrhea typically involves infectious triggers and malnutrition, and is termed syndromic persistent diarrhea. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Syndromic persistent diarrhea'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43609?source=see_link\">",
"       \"Persistent diarrhea in children in developing countries\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/1\">",
"      Bhutta ZA, Ghishan F, Lindley K, et al. Persistent and chronic diarrhea and malabsorption: Working Group report of the second World Congress of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2004; 39 Suppl 2:S711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/2\">",
"      Binder HJ. Causes of chronic diarrhea. N Engl J Med 2006; 355:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/3\">",
"      Guarino A, Spagnuolo MI, Russo S, et al. Etiology and risk factors of severe and protracted diarrhea. J Pediatr Gastroenterol Nutr 1995; 20:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/4\">",
"      Catassi C, Fabiani E, Spagnuolo MI, et al. Severe and protracted diarrhea: results of the 3-year SIGEP multicenter survey. Working Group of the Italian Society of Pediatric Gastroenterology and Hepatology (SIGEP). J Pediatr Gastroenterol Nutr 1999; 29:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/5\">",
"      Guarino A, De Marco G, Italian National Network for Pediatric Intestinal Failure. Natural history of intestinal failure, investigated through a national network-based approach. J Pediatr Gastroenterol Nutr 2003; 37:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/6\">",
"      Vanderhoof JA. Chronic diarrhea. Pediatr Rev 1998; 19:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/7\">",
"      Gibbons T, Fuchs GJ. Chronic enteropathy: clinical aspects. Nestle Nutr Workshop Ser Pediatr Program 2007; 59:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/8\">",
"      Fine KD, Schiller LR. AGA technical review on the evaluation and management of chronic diarrhea. Gastroenterology 1999; 116:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/9\">",
"      Mbori-Ngacha DA, Otieno JA, Njeru EK, Onyango FE. Prevalence of persistent diarrhoea in children aged 3-36 months at the Kenyatta National Hospital, Nairobi, Kenya. East Afr Med J 1995; 72:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/10\">",
"      Karim AS, Akhter S, Rahman MA, Nazir MF. Risk factors of persistent diarrhea in children below five years of age. Indian J Gastroenterol 2001; 20:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/11\">",
"      Ngan PK, Khanh NG, Tuong CV, et al. Persistent diarrhea in Vietnamese children: a preliminary report. Acta Paediatr 1992; 81 Suppl 381:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/12\">",
"      Vernacchio L, Vezina RM, Mitchell AA, et al. Characteristics of persistent diarrhea in a community-based cohort of young US children. J Pediatr Gastroenterol Nutr 2006; 43:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/13\">",
"      Malek MA, Curns AT, Holman RC, et al. Diarrhea- and rotavirus-associated hospitalizations among children less than 5 years of age: United States, 1997 and 2000. Pediatrics 2006; 117:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/14\">",
"      Schiller LR. Chronic diarrhea. Gastroenterology 2004; 127:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/15\">",
"      Hyman PE, Milla PJ, Benninga MA, et al. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology 2006; 130:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/16\">",
"      Kleinman RE. Chronic nonspecific diarrhea of childhood. Nestle Nutr Workshop Ser Pediatr Program 2005; 56:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/17\">",
"      Cohen SA, Hendricks KM, Mathis RK, et al. Chronic nonspecific diarrhea: dietary relationships. Pediatrics 1979; 64:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/18\">",
"      Guarino A, Canani RB, Russo S, et al. Oral immunoglobulins for treatment of acute rotaviral gastroenteritis. Pediatrics 1994; 93:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/19\">",
"      Grimwood K, Carzino R, Barnes GL, Bishop RF. Patients with enteric adenovirus gastroenteritis admitted to an Australian pediatric teaching hospital from 1981 to 1992. J Clin Microbiol 1995; 33:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/20\">",
"      Boudraa G, Benbouabdellah M, Hachelaf W, et al. Effect of feeding yogurt versus milk in children with acute diarrhea and carbohydrate malabsorption. J Pediatr Gastroenterol Nutr 2001; 33:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/21\">",
"      What has happened to carbohydrate intolerance following gastroenteritis? Lancet 1987; 1:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/22\">",
"      Sandhu BK, Isolauri E, Walker-Smith JA, et al. A multicentre study on behalf of the European Society of Paediatric Gastroenterology and Nutrition Working Group on Acute Diarrhoea. Early feeding in childhood gastroenteritis. J Pediatr Gastroenterol Nutr 1997; 24:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/23\">",
"      Walker-Smith JA, Sandhu BK, Isolauri E, et al. Guidelines prepared by the ESPGAN Working Group on Acute Diarrhoea. Recommendations for feeding in childhood gastroenteritis. European Society of Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 1997; 24:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/24\">",
"      Isolauri E. Probiotics for infectious diarrhoea. Gut 2003; 52:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/25\">",
"      Ga&oacute;n D, Garc&iacute;a H, Winter L, et al. Effect of Lactobacillus strains and Saccharomyces boulardii on persistent diarrhea in children. Medicina (B Aires) 2003; 63:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/26\">",
"      Swindells J, Brenwald N, Reading N, Oppenheim B. Evaluation of diagnostic tests for Clostridium difficile infection. J Clin Microbiol 2010; 48:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/27\">",
"      Naik S, Smith F, Ho J, et al. Staphylococcal enterotoxins G and I, a cause of severe but reversible neonatal enteropathy. Clin Gastroenterol Hepatol 2008; 6:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/28\">",
"      Farthing MJ. Diarrhoea: a significant worldwide problem. Int J Antimicrob Agents 2000; 14:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/29\">",
"      Fraser D, Dagan R, Porat N, et al. Persistent diarrhea in a cohort of Israeli Bedouin infants: role of enteric pathogens and family and environmental factors. J Infect Dis 1998; 178:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/30\">",
"      Ochoa TJ, Salazar-Lindo E, Cleary TG. Management of children with infection-associated persistent diarrhea. Semin Pediatr Infect Dis 2004; 15:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/31\">",
"      Bhandari N, Bhan MK, Sazawal S, et al. Association of antecedent malnutrition with persistent diarrhoea: a case-control study. BMJ 1989; 298:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/32\">",
"      Evaluation of an algorithm for the treatment of persistent diarrhoea: a multicentre study. International Working Group on Persistent Diarrhoea. Bull World Health Organ 1996; 74:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/33\">",
"      Khoshoo V, Bhan MK, Jayashree S, et al. Rotavirus infection and persistent diarrhoea in young children. Lancet 1990; 336:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/34\">",
"      Tovo PA, de Martino M, Gabiano C, et al. Prognostic factors and survival in children with perinatal HIV-1 infection. The Italian Register for HIV Infections in Children. Lancet 1992; 339:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/35\">",
"      Guarino A, Albano F, Canani RB, Bruzzese E. HIV, fatal rotavirus infection, and treatment options. Lancet 2002; 359:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/36\">",
"      Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med 2010; 362:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/37\">",
"      Muise AM, Snapper SB, Kugathasan S. The age of gene discovery in very early onset inflammatory bowel disease. Gastroenterology 2012; 143:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/38\">",
"      El-Matary W, Girgis S, Huynh H, et al. Microscopic colitis in children. Dig Dis Sci 2010; 55:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/39\">",
"      Haas JT, Winter HS, Lim E, et al. DGAT1 mutation is linked to a congenital diarrheal disorder. J Clin Invest 2012; 122:4680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/40\">",
"      Goulet O, Salomon J, Ruemmele F, et al. Intestinal epithelial dysplasia (tufting enteropathy). Orphanet J Rare Dis 2007; 2:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/41\">",
"      Pecache N, Patole S, Hagan R, et al. Neonatal congenital microvillus atrophy. Postgrad Med J 2004; 80:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/42\">",
"      Al Makadma AS, Al-Akash SI, Al Dalaan I, et al. Congenital sodium diarrhea in a neonate presenting as acute renal failure. Pediatr Nephrol 2004; 19:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/43\">",
"      H&ouml;glund P. SLC26A3 and congenital chloride diarrhoea. Novartis Found Symp 2006; 273:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/44\">",
"      H&ouml;glund P, Haila S, Socha J, et al. Mutations of the Down-regulated in adenoma (DRA) gene cause congenital chloride diarrhoea. Nat Genet 1996; 14:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/45\">",
"      Lechner S, Ruemmele FM, Zankl A, et al. Significance of molecular testing for congenital chloride diarrhea. J Pediatr Gastroenterol Nutr 2011; 53:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/46\">",
"      Wedenoja S, H&ouml;glund P, Holmberg C. Review article: the clinical management of congenital chloride diarrhoea. Aliment Pharmacol Ther 2010; 31:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/47\">",
"      Hihnala S, H&ouml;glund P, Lammi L, et al. Long-term clinical outcome in patients with congenital chloride diarrhea. J Pediatr Gastroenterol Nutr 2006; 42:369.",
"     </a>",
"    </li>",
"    <li>",
"     Martin MG, Wright EM. Congenital intestinal transport defects. In: Pediatric Gastrointestinal Disease, 4th, Walker, Goulet O, Kleinman RE, et al (Eds), BC Decker, Ontario 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/49\">",
"      Aichbichler BW, Zerr CH, Santa Ana CA, et al. Proton-pump inhibition of gastric chloride secretion in congenital chloridorrhea. N Engl J Med 1997; 336:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/50\">",
"      Canani RB, Terrin G, Cirillo P, et al. Butyrate as an effective treatment of congenital chloride diarrhea. Gastroenterology 2004; 127:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/51\">",
"      Wedenoja S, Holmberg C, H&ouml;glund P. Oral butyrate in treatment of congenital chloride diarrhea. Am J Gastroenterol 2008; 103:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/52\">",
"      Berni Canani R, Terrin G, Cardillo G, et al. Congenital diarrheal disorders: improved understanding of gene defects is leading to advances in intestinal physiology and clinical management. J Pediatr Gastroenterol Nutr 2010; 50:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/53\">",
"      Heinz-Erian P, M&uuml;ller T, Krabichler B, et al. Mutations in SPINT2 cause a syndromic form of congenital sodium diarrhea. Am J Hum Genet 2009; 84:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/54\">",
"      M&uuml;ller T, Wijmenga C, Phillips AD, et al. Congenital sodium diarrhea is an autosomal recessive disorder of sodium/proton exchange but unrelated to known candidate genes. Gastroenterology 2000; 119:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/55\">",
"      M&uuml;ller T, Hess MW, Schiefermeier N, et al. MYO5B mutations cause microvillus inclusion disease and disrupt epithelial cell polarity. Nat Genet 2008; 40:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/56\">",
"      Erickson RP, Larson-Thom&eacute; K, Valenzuela RK, et al. Navajo microvillous inclusion disease is due to a mutation in MYO5B. Am J Med Genet A 2008; 146A:3117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/57\">",
"      Ruemmele FM, Schmitz J, Goulet O. Microvillous inclusion disease (microvillous atrophy). Orphanet J Rare Dis 2006; 1:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/58\">",
"      Halac U, Lacaille F, Joly F, et al. Microvillous inclusion disease: how to improve the prognosis of a severe congenital enterocyte disorder. J Pediatr Gastroenterol Nutr 2011; 52:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/59\">",
"      Sivagnanam M, Mueller JL, Lee H, et al. Identification of EpCAM as the gene for congenital tufting enteropathy. Gastroenterology 2008; 135:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/60\">",
"      Sivagnanam M, Schaible T, Szigeti R, et al. Further evidence for EpCAM as the gene for congenital tufting enteropathy. Am J Med Genet A 2010; 152A:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/61\">",
"      Lemale J, Coulomb A, Dubern B, et al. Intractable diarrhea with tufting enteropathy: a favorable outcome is possible. J Pediatr Gastroenterol Nutr 2011; 52:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/62\">",
"      Al-Mayouf SM, Alswaied N, Alkuraya FS, et al. Tufting enteropathy and chronic arthritis: a newly recognized association with a novel EpCAM gene mutation. J Pediatr Gastroenterol Nutr 2009; 49:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/63\">",
"      Roche O, Putterman M, Salomon J, et al. Superficial punctate keratitis and conjunctival erosions associated with congenital tufting enteropathy. Am J Ophthalmol 2010; 150:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/64\">",
"      Sivagnanam M, Janecke AR, M&uuml;ller T, et al. Case of syndromic tufting enteropathy harbors SPINT2 mutation seen in congenital sodium diarrhea. Clin Dysmorphol 2010; 19:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/65\">",
"      Wang J, Cortina G, Wu SV, et al. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N Engl J Med 2006; 355:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/66\">",
"      Ohsie S, Gerney G, Gui D, et al. A paucity of colonic enteroendocrine and/or enterochromaffin cells characterizes a subset of patients with chronic unexplained diarrhea/malabsorption. Hum Pathol 2009; 40:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/67\">",
"      Oelkers P, Kirby LC, Heubi JE, Dawson PA. Primary bile acid malabsorption caused by mutations in the ileal sodium-dependent bile acid transporter gene (SLC10A2). J Clin Invest 1997; 99:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/68\">",
"      Johnston I, Nolan J, Pattni SS, Walters JR. New insights into bile acid malabsorption. Curr Gastroenterol Rep 2011; 13:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/69\">",
"      Mart&iacute;n MG, Turk E, Lostao MP, et al. Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat Genet 1996; 12:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/70\">",
"      Treem WR. Congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr 1995; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/71\">",
"      L&uuml;cke T, Keiser M, Illsinger S, et al. Congenital and putatively acquired forms of sucrase-isomaltase deficiency in infancy: effects of sacrosidase therapy. J Pediatr Gastroenterol Nutr 2009; 49:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/72\">",
"      Sander P, Alfalah M, Keiser M, et al. Novel mutations in the human sucrase-isomaltase gene (SI) that cause congenital carbohydrate malabsorption. Hum Mutat 2006; 27:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/73\">",
"      Robayo-Torres CC, Opekun AR, Quezada-Calvillo R, et al. 13C-breath tests for sucrose digestion in congenital sucrase isomaltase-deficient and sacrosidase-supplemented patients. J Pediatr Gastroenterol Nutr 2009; 48:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/74\">",
"      Roy CC, Levy E, Green PH, et al. Malabsorption, hypocholesterolemia, and fat-filled enterocytes with increased intestinal apoprotein B. Chylomicron retention disease. Gastroenterology 1987; 92:390.",
"     </a>",
"    </li>",
"    <li>",
"     Goday PS, Cohen MB. Secretory tumors. In: Pediatric Gastrointestinal Disease, 4th, Walker WA, Goulet O, Kleinman RE, et al (Eds), BC Decker, Ontario 2004. p.1057.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/5/5210/abstract/76\">",
"      Carter MC, Metcalfe DD. Paediatric mastocytosis. Arch Dis Child 2002; 86:315.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5877 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5210=[""].join("\n");
var outline_f5_5_5210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE AND MORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      FUNCTIONAL DIARRHEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INFECTIOUS CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Postenteritis syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Parasites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Syndromic persistent diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IMMUNE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ABNORMAL IMMUNE RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Allergic enteropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3479327\">",
"      Microscopic and collagenous colitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Autoimmune enteropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MALDIGESTION OF FAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other causes of pancreatic insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27779023\">",
"      CHOLERHEIC DIARRHEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      GASTROINTESTINAL PROTEIN LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Mucosal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Lymphatic obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      BOWEL OBSTRUCTION OR DYSMOTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Hirschsprung's disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Intestinal pseudoobstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      CONGENITAL SECRETORY AND OSMOTIC DIARRHEAS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Secretory diarrheas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3479576\">",
"      - Congenital chloride diarrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3479583\">",
"      - Congenital sodium diarrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3479590\">",
"      - Microvillus inclusion disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3479597\">",
"      - Tufting enteropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3479604\">",
"      - Enteric anendocrinosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Osmotic diarrheas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Steatorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      NEUROENDOCRINE TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Gastrinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      VIPoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      FACTITIOUS DIARRHEA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5877\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5877|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/32/26125\" title=\"table 1\">",
"      Causes of chronic diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/7/20606\" title=\"table 2\">",
"      Genetic causes of congenital diarrhea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23221?source=related_link\">",
"      Anthelminthic therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17335?source=related_link\">",
"      Antiprotozoal therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/55/43897?source=related_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35511?source=related_link\">",
"      Approach to the diagnosis of chronic diarrhea in children in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/45/29400?source=related_link\">",
"      Chronic complications of the short bowel syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=related_link\">",
"      Chronic intestinal pseudo-obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=related_link\">",
"      Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=related_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/6/28777?source=related_link\">",
"      Clostridium difficile infection in children: Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=related_link\">",
"      Clostridium difficile infection in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15354?source=related_link\">",
"      Constipation in children: Etiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29513?source=related_link\">",
"      Diagnostic approach to lower gastrointestinal bleeding in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=related_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38551?source=related_link\">",
"      Evaluation of the HIV-infected patient with diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6246?source=related_link\">",
"      Factitious diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/15/25850?source=related_link\">",
"      IPEX: Immune dysregulation, polyendocrinopathy, enteropathy, X-linked",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/56/27530?source=related_link\">",
"      Lymphocytic and collagenous colitis (microscopic colitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7929?source=related_link\">",
"      Management of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/3/3130?source=related_link\">",
"      Natural history and classification of pediatric HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43609?source=related_link\">",
"      Persistent diarrhea in children in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=related_link\">",
"      Protein-losing gastroenteropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33400?source=related_link\">",
"      Shwachman-Diamond syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=related_link\">",
"      The VIPoma syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_5_5211="Criteria 12 lead ECG";
var content_f5_5_5211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for immediate 12-lead ECG",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        &ge;",
"        <strong>",
"         30 years old with chest pain",
"        </strong>",
"        (excluding respiratory infection or trauma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;",
"        <strong>",
"         50 years old with chest pain OR:",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rapid heart beat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Difficulty breathing or shortness of breath",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Graff L, Palmer AC, LaMonica P, Wolf S. Triage of patients for a rapid (5-minute) electrocardiogram: A rule based on presenting chief complaints. Annals Emerg Med. December 2000; 36:554.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5211=[""].join("\n");
var outline_f5_5_5211=null;
var title_f5_5_5212="Patient counseling for ESA use";
var content_f5_5_5212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55973&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient counseling regarding the risks and benefits of therapy with an erythropoiesis-stimulating agent for anemia associated with chemotherapy for malignant disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        The following issues should be discussed with patients regarding the risks and benefits of therapy with an erythropoiesis stimulating agent (ESA) for symptomatic anemia in patients receiving chemotherapy for malignant disease:",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        1. The goal of ESA therapy for patients with chemotherapy-induced anemia is to reduce red blood cell (RBC) transfusion requirements.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Although there are some suggestions that ESA treatment may improve fatigue or quality of life (QOL) in some patients, the primary goal is to reduce transfusion requirements.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. There are potential harms and benefits of ESAs versus RBC transfusions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. ESAs have been found to shorten overall survival and/or speed tumor growth in some patients with cancer. It is for this reason that the US Food and Drug Administration (FDA) has indicated that ESAs should not be given to patients who are being treated for cancer when the goal is to cure the patient (of cancer).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. ESAs have risks of adverse events, such as blood clots, and individual risk factors for blood clots have to be considered when weighing the risks versus benefits.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6. ESAs are not recommended for patients with cancer who are not receiving chemotherapy or who are receiving radiotherapy without chemotherapy, because ESAs have been associated with an increased risk of death in such patients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7. An acknowledgment form needs to be signed by patients to confirm that they have talked to their health care professional about the risks of ESAs.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Oncol Pract 2010; 6:317.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5212=[""].join("\n");
var outline_f5_5_5212=null;
var title_f5_5_5213="Myocarditis versus IDC";
var content_f5_5_5213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64625&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 483px\">",
"   <div class=\"ttl\">",
"    Similar outcome in myocarditis and IDC",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 463px; height: 253px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of survival in 27 patients with biopsy-proved myocarditis (definite or borderline) versus 58 patients with idiopathic dilated cardiomyopathy (IDC) who had a negative endomyocardial biopsy. The survival rates were equivalent in the two disorders.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Grogan, M, Redfield, MM, Bailey, KR, et al, J Am Coll Cardiol 1995; 26:80.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5213=[""].join("\n");
var outline_f5_5_5213=null;
var title_f5_5_5214="Motility medium Shigella";
var content_f5_5_5214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Motility testing on nonlactose fermenting gram negative rods",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 221px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left tube: The nonmotile Shigella does not migrate away from the central stab line in the agar. Right tube: Motile Proteus produces visible opacification of the agar away from the central stab line. The color difference between the two samples is unrelated to the motility test.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael S Glickman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5214=[""].join("\n");
var outline_f5_5_5214=null;
var title_f5_5_5215="Endoscopic component separation technique rectus muscle release";
var content_f5_5_5215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76703&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic component separation technique rectus muscle release",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The skin and subcutaneous tissue flaps are carefully dissected from the rectus sheath for no more than 1 to 2 cm, taking special care to avoid disruption of the perforating vessels from the anterior surface of the rectus muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Lowe JB, Garza JR, Bowman JL, et al. Endoscopically assisted \"components separation\" for closure of abdominal wall defects. Plast Reconstr Surg 2000; 105:720.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_5_5215=[""].join("\n");
var outline_f5_5_5215=null;
